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Abstract
Background
In the UK, dementia affects 5% of the population aged over 65 years and 25% of those over 85 years. Frontotemporal
dementia (FTD) represents one subtype and is thought to account for up to 16% of all degenerative dementias. Although the
core of the diagnostic process in dementia rests firmly on clinical and cognitive assessments, a wide range of investigations
are available to aid diagnosis.
Regional cerebral blood flow (rCBF) single-photon emission computed tomography (SPECT) is an established clinical tool
that uses an intravenously injected radiolabelled tracer to map blood flow in the brain. In FTD the characteristic pattern seen
is hypoperfusion of the frontal and anterior temporal lobes. This pattern of blood flow is different to patterns seen in other
subtypes of dementia and so can be used to differentiate FTD.
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It has been proposed that a diagnosis of FTD, (particularly early stage), should be made not only on the basis of clinical
criteria but using a combination of other diagnostic findings, including rCBF SPECT. However, more extensive testing comes
at a financial cost, and with a potential risk to patient safety and comfort.
Objectives
To determine the diagnostic accuracy of rCBF SPECT for diagnosing FTD in populations with suspected dementia in
secondary/tertiary healthcare settings and in the differential diagnosis of FTD from other dementia subtypes.
Search methods
Our search strategy used two concepts: (a) the index test and (b) the condition of interest. We searched citation databases,
including MEDLINE (Ovid SP), EMBASE (Ovid SP), BIOSIS (Ovid SP), Web of Science Core Collection (ISI Web of
Science), PsycINFO (Ovid SP), CINAHL (EBSCOhost) and LILACS (Bireme), using structured search strategies appropriate
for each database. In addition we searched specialised sources of diagnostic test accuracy studies and reviews including:
MEDION (Universities of Maastricht and Leuven), DARE (Database of Abstracts of Reviews of Effects) and HTA (Health
Technology Assessment) database.
We requested a search of the Cochrane Register of Diagnostic Test Accuracy Studies and used the related articles feature in
PubMed to search for additional studies. We tracked key studies in citation databases such as Science Citation Index and
Scopus to ascertain any further relevant studies. We identified ‘grey’ literature, mainly in the form of conference abstracts,
through the Web of Science Core Collection, including Conference Proceedings Citation Index and Embase. The most recent
search for this review was run on the 1 June 2013.
Following title and abstract screening of the search results, full-text papers were obtained for each potentially eligible study.
These papers were then independently evaluated for inclusion or exclusion.
Selection criteria
We included both case-control and cohort (delayed verification of diagnosis) studies. Where studies used a case-control
design we included all participants who had a clinical diagnosis of FTD or other dementia subtype using standard clinical
diagnostic criteria. For cohort studies, we included studies where all participants with suspected dementia were administered
rCBF SPECT at baseline. We excluded studies of participants from selected populations (e.g. post-stroke) and studies of
participants with a secondary cause of cognitive impairment.
Data collection and analysis
Two review authors extracted information on study characteristics and data for the assessment of methodological quality and
the investigation of heterogeneity. We assessed the methodological quality of each study using the QUADAS-2 (Quality
Assessment of Diagnostic Accuracy Studies) tool. We produced a narrative summary describing numbers of studies that
were found to have high/low/unclear risk of bias as well as concerns regarding applicability. To produce 2 x 2 tables, we
dichotomised the rCBF SPECT results (scan positive or negative for FTD) and cross-tabulated them against the results for
the reference standard. These tables were then used to calculate the sensitivity and specificity of the index test. Meta-
analysis was not performed due to the considerable between-study variation in clinical and methodological characteristics.
Main results
Eleven studies (1117 participants) met our inclusion criteria. These consisted of six case-control studies, two retrospective
cohort studies and three prospective cohort studies. Three studies used single-headed camera SPECT while the remaining
eight used multiple-headed camera SPECT. Study design and methods varied widely. Overall, participant selection was not
well described and the studies were judged as having either high or unclear risk of bias. Often the threshold used to define a
positive SPECT result was not predefined and the results were reported with knowledge of the reference standard. Concerns
regarding applicability of the studies to the review question were generally low across all three domains (participant selection,
index test and reference standard).
Sensitivities and specificities for differentiating FTD from non-FTD ranged from 0.73 to 1.00 and from 0.80 to 1.00,
respectively, for the three multiple-headed camera studies. Sensitivities were lower for the two single-headed camera
studies; one reported a sensitivity and specificity of 0.40 (95% confidence interval (CI) 0.05 to 0.85) and 0.95 (95% CI 0.90 to
0.98), respectively, and the other a sensitivity and specificity of 0.36 (95% CI 0.24 to 0.50) and 0.92 (95% CI 0.88 to 0.95),
respectively.
Eight of the 11 studies which used SPECT to differentiate FTD from Alzheimer's disease used multiple-headed camera
SPECT. Of these studies, five used a case-control design and reported sensitivities of between 0.52 and 1.00, and
specificities of between 0.41 and 0.86. The remaining three studies used a cohort design and reported sensitivities of
between 0.73 and 1.00, and specificities of between 0.94 and 1.00. The three studies that used single-headed camera
SPECT reported sensitivities of between 0.40 and 0.80, and specificities of between 0.61 and 0.97.
Authors' conclusions
At present, we would not recommend the routine use of rCBF SPECT in clinical practice because there is insufficient
evidence from the available literature to support this.
Further research into the use of rCBF SPECT for differentiating FTD from other dementias is required. In particular, protocols
should be standardised, study populations should be well described, the threshold for 'abnormal' scans predefined and clear
details given on how scans are analysed. More prospective cohort studies that verify the presence or absence of FTD during
a period of follow up should be undertaken.
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Plain language summary
Regional Cerebral Blood Flow SPECT for detection of Frontotemporal dementia in people with suspected
dementia
Background
This review focused on one type of dementia, frontotemporal dementia (FTD). This neurodegenerative disease affects the
frontal and temporal lobes of the brain and accounts for up to 16% of all degenerative dementias. People who have this
disease may develop changes in their behaviour, speech or ability to plan. It is important to identify people with FTD correctly
as the disease course and response to treatment differs from other dementias such as Alzheimer’s disease.
One test used by healthcare professionals to help make a diagnosis of FTD, is regional cerebral blood flow single photon
emission computed tomography (rCBF SPECT). This investigation allows visualisation of blood flow within the brain. In FTD
it is thought that the pattern of blood flow to the brain can be used to tell the difference between FTD and other dementias.
However, it is not clear whether using rCBF SPECT in this way improves our ability to make an accurate diagnosis of FTD.
As all investigations come with a financial cost, it is important that their benefit is known.
Aim: This review assessed the evidence regarding the accuracy of rCBF SPECT in detecting FTD in people with suspected
dementia.
Study characteristics
We searched many databases for all papers with FTD and rCBF SPECT as their focus. These papers were reviewed
independently by several researchers. After application of inclusion and exclusion criteria, eleven studies including 299
individuals with FTD were available for this review. The studies were published over a 21-year period, with a study size
ranging from 27 to 363 participants, mainly recruited from University clinics, tertiary referral centres or memory clinics. Of the
11 studies, three used single-headed (single detector) gamma cameras, a method no longer used in clinical practice today.
Evidence is current to June 2013.
Quality of the evidence
The majority of studies were at high risk of bias due to insufficient details on how participants were selected and how the
rCBF SPECT scans were conducted and analysed. The main limitations of the review were poor reporting, variability of study
design and a lack of standardisation of image interpretation between centres.
Key findings
Due to small study numbers and large variation in how the studies were carried out, we are unable at present to recommend
the routine use of rCBF SPECT for diagnosing FTD in clinical practice.
Background 
Target condition being diagnosed
Dementia is a progressive syndrome of global cognitive impairment. In the UK, it affects 5% of the population
over 65 years and 25% of those over 85 years (Alzheimer's Society 2007). In 2010, there were approximately 36
million people living with dementia worldwide (Alzheimer's Disease International 2010).  The greatest increases in
prevalence will be seen in developing regions.  By 2040, China and its western-Pacific neighbours are predicted to have
26 million people living with dementia (Ferri 2005).
Dementia encompasses a group of neurodegenerative disorders that are characterised by a progressive loss in
cognitive function and the ability to perform activities of daily living; these losses can be accompanied by
neuropsychiatric symptoms and challenging behaviours of varying type and severity. The underlying pathology is
usually degenerative and subtypes of dementia include Alzheimer's disease (AD), vascular dementia (VaD), dementia
with Lewy bodies (DLB) and frontotemporal dementia (FTD) (previously known as Pick's disease). There may be
considerable overlap in clinical and pathological presentations between subtypes (MRC CFAS 2001) and there is
often co-existence of AD and VaD (Matthews 2009; Savva 2009). 
FTD is a neurodegenerative disease that affects the anterior temporal and frontal lobes. It is thought to account for up to 16%
of all degenerative dementias (Miller 1997; Ratnavalli 2002) and is the second most common young-onset dementia (
Seelaar 2011). It is characterised clinically by progressive behavioural change, executive dysfunction and language
difficulties, and comprises three main clinical syndromes: behavioural variant FTD (bvFTD), semantic dementia (SD) and
progressive non-fluent aphasia (PNFA). Although the core of the diagnostic process in dementia rests firmly on clinical and
cognitive assessments, a wide range of investigations are available to further aid diagnosis. These include blood and
cerebrospinal fluid tests, as well as neuroimaging modalities such as magnetic resonance imaging (MRI), regional cerebral
blood flow (rCBF) single-photon emission computed tomography (SPECT) and regional cerebral metabolism 18F-
fluorodeoxyglucose positron emission tomography (FDG-PET). Structural imaging in individuals with FTD using MRI shows
frontal and temporal atrophy, which can be asymmetrical; rCBF SPECT imaging shows anterior frontal or temporal
hypoperfusion.
The management of individuals with dementia requires an accurate diagnosis of the underlying neurodegenerative process
in order to guide prognosis, early therapeutic intervention, and advice regarding heritability and social and environmental
management. This is particularly important in FTD, which has a wide range of presentations that often overlap significantly
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with those of other dementias, especially AD and VaD. Accurate diagnosis of FTD as the underlying aetiology of the
dementing illness is important as treatment with cholinesterase inhibitors (used in AD) may have adverse effects in
individuals with FTD.
The clinical criteria used to diagnose FTD have evolved over time. In 1994, the Lund-Manchester group produced a set
of research criteria for a diagnosis of FTD(Lund and Manchester Groups 1994). These emphasised the importance of
core behavioural and affective symptoms, progressive reduction in speech, and profound failure on ‘frontal lobe’ tests
in the absence of severe amnesia, aphasia or perceptuospatial disorder. In 1998, Neary and colleagues further refined
the Lund-Manchester criteria and renamed the condition frontotemporal lobar degeneration (FTLD) (Neary 1998).
They provided clinical descriptions of bvFTD, PNFA and SD. These criteria recognised the clinical heterogeneity
within the FTLD spectrum and provided diagnostic guidelines for all three syndromes. They also made a distinction
between core and supportive diagnostic features. Limitations of these criteria were the ambiguity of behavioural
descriptors and inflexibility in the application of criteria (i.e. the requirement that all five core features be manifest).
In 2001, McKhann and colleagues developed criteria to enable clinicians to identify individuals with FTD and
expedite their referral for evaluation (McKhann 2001). The overall clinical spectrum was renamed FTD and the
clinical criteria were simplified into two distinct presentations depending on whether progressive changes were
apparent in behaviour or language. It is thought that, although useful clinically, these criteria lack sufficient
specificity to be applicable for research purposes, particularly in the case of progressive aphasia syndromes (Rascovsky
2007). More recently, the International Behavioural Variant FTD Consortium (FTDC) developed revised guidelines
for the diagnosis of bvFTD. It is thought that these revised criteria improve diagnostic accuracy compared with
previously established criteria (Rascovsky 2011).
A number of studies have established that the currently accepted clinical criteria for FTD are relatively insensitive,
particularly in the early stages of the disease process where the sensitivity of clinical criteria decreases to 37% (Seelaar
2011). In autopsy-proven studies, the current clinical criteria correctly classify approximately 80% to 90% of bvFTD (
Seelaar 2011).
It has been proposed that a diagnosis of FTD, particularly in the early stages, should be made not only on clinical criteria but
using a combination of other diagnostic findings, including rCBF SPECT. However, more extensive testing comes at a
financial cost and with a potential risk to patient safety and comfort. Thus it is important that additional diagnostic tests are of
proven benefit. rCBF SPECT is a neuroimaging tool that has been found by some to improve our ability to differentiate FTD
from other dementias (Miller 1997; Rascovsky 2011), although its use is controversial (Knopman 2001).
Index test(s)
rCBF SPECT is an established non-invasive clinical tool that maps blood flow to different areas of the brain. rCBF is thought
to indirectly reflect neural activity in each brain region at rest. In order to depict the patterns of blood flow within the brain, a
radiopharmaceutical is injected into the body, which is rapidly removed from the blood by brain tissue. The radiotracers most
commonly used are 99mtechnetium-hexamethyl-propylenamine oxime (99mTc-HMPAO) or 99mtechnetium-ethyl-
cysteinate dimer (99mTc-ECD). The radiotracer enters the brain at first pass, with its incorporation proportional to the rCBF in
the first few minutes after injection. Modifications in rCBF after injection do not change the initial distribution of the tracer
because of intracellular trapping.
Shortly after injection, the person is scanned using a gamma camera that images the radioactive emissions from the
individual at multiple angles around the head. These individual images are reconstructed to create a three-dimensional
map of cerebral blood flow. According to relevant guidelines (Juni 2009; Kapucu 2009), at least 5 million counts should be
acquired; this is rarely practical with single-headed cameras as the total acquisition time will approach one hour, and most
systems now use multiple-headed cameras. The amount of clinically significant hypoperfusion is generally determined by
visual inspection, although computerised analysis, commonly achieved by comparing the scan being taken to a database of
scans from healthy individuals, is increasingly popular. There are potential challenges with study interpretation due to the
differing methods used in analysis, pre- or post-processing of images and the advances seen in rCBF SPECT technology
over time. These factors are discussed in more detail below.
Individuals with different dementias are thought to have different patterns of abnormal blood flow. In FTD, perfusion
tends to be reduced in the frontal and anterior temporal lobes (Miller 1997), whereas individuals with AD demonstrate
reduced flow in the medial temporal, superior temporal, parietal, posterior cingulate cortex and precuneus. These
patterns have been used to differentiate FTD from AD (Catafau 2001) with a sensitivity of 71% and specificity of 78.2%
(Miller 1997).
rCBF SPECT is usually used clinically when the presence or type of dementia is uncertain after clinical assessment,
neuropsychological testing and structural imaging. This imaging modality has an advantage over structural neuroimaging
techniques as rCBF changes may precede structural changes. Compared with FDG-PET, which depicts cerebral
metabolism, rCBF SPECT is more widely available.
Clinical Pathway 
Presentation
In the UK, people with suspected dementia usually present first to their general practitioner who may administer basic
screening tests (blood tests and simple tests of cognitive function) and may potentially refer them to a hospital memory
clinic. At this stage, other physical or mental disorders, for example depression or hypothyroidism, which might be
contributing to the cognitive impairment, are typically excluded or treated. Unlike dementias, such as AD, which usually have
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memory loss as their first symptom, FTD more commonly presents with personality changes, disinhibited behaviour, mood
disorder and even psychosis. As a result, this diagnosis may be missed initially, with the individual referred for specialist
assessment only when a diagnosis of FTD is suspected.
Standard diagnostic practice
The standard assessment of dementia includes taking a history, a clinical examination (including neurological,
mental state and cognitive examinations) and an interview with a relative or other informant. A neuroradiological
examination (computed tomography (CT) or MRI of the brain) is also recommended in most recent guidelines (McKhann
2011; NICE 2006). Individuals may also receive a full neuropsychological assessment, if appropriate, before a diagnosis of
dementia is made. Diagnostic assessment pathways may vary between countries and diagnoses may be made by a variety
of specialists including neurologists and geriatricians. 
A diagnosis of dementia is defined as a deficit in more than two cognitive domains of sufficient degree to impair functional
activities. These symptoms are usually progressive over a period of at least several months and should not be attributable to
any other brain disease. The World Health Organization International Classification of Diseases 10th revision (ICD-10)
diagnostic criteria for dementia are detailed in Appendix 1.
The FTD subtype of dementia is usually diagnosed on the basis of clinical presentation, according to currently
accepted clinical criteria (Neary 1998; Rascovsky 2007a). rCBF SPECT is sometimes used to help establish the diagnosis of
FTD, but is usually carried out only in secondary or tertiary referral centres.
Role of index test(s)
How might the index test improve diagnoses, treatments and outcomes?
If FTD can be diagnosed at an early stage, this will help people with dementia, their families and potential carers to
make timely plans for the future. In the early stages of the disease, and particularly in young-onset bvFTD, FTD can be
misdiagnosed as another subtype of dementia (often AD). Coupled with appropriate contingency planning, proper
recognition of the disease may also help to avoid costly admissions to hospital or institutional care (NAO 2007). In addition,
the accurate early identification of FTD may improve opportunities for the use of newly evolving interventions designed to
delay or prevent the progression to more debilitating stages of dementia.  
Alternative test(s)
Alternative tests used in the diagnosis of FTD include CT, MRI and PET. These modalities were not included in this review
as there are currently no standard practice tests available for the diagnosis of FTD.
Rationale
The public health burden of dementia is of growing concern. With the changing age structure of populations in both high-
and low-income countries, the prevalence of dementia is increasing (Ferri 2005). At the population level, there
are major implications for service provision and planning, given that this condition leads to progressive functional
dependence over several years. In the UK, it is estimated that the annual expenditure on dementia care is
GBP17 billion (Alzheimer's Society 2007), and the worldwide cost of dementia in 2010 was USD604 billion (Alzheimer's
Disease International 2010). Accurate early diagnosis of dementia and the subtype of FTD may help in planning appropriate
care and reducing costs.
It is important that expensive and invasive diagnostic tests are of proven benefit over more established clinical and
imaging assessments. The clinical use of SPECT in differentiating AD, VaD and FTD has been recognised in certain
diagnostic guidelines. NICE 2006 recommend that rCBF SPECT should be used to differentiate AD, VaD and FTD if the
diagnosis is in doubt. Rascovsky 2011 state that the additional use of SPECT could give greater certainty to a diagnosis of
FTD. However, other guidelines such as Knopman 2001 do not recommend SPECT for routine use in either initial or
differential diagnosis. Thus, a systematic review of the diagnostic accuracy of rCBF SPECT in FTD is needed.
Objectives 
Primary objectives
To determine the diagnostic accuracy of rCBF SPECT in diagnosing FTD in populations with suspected dementia in
secondary/tertiary healthcare settings
To determine the accuracy of rCBF SPECT in the differential diagnosis of FTD from other dementia subtypes
Secondary objectives
To highlight the quality and quantity of research evidence available regarding the diagnostic accuracy of rCBF SPECT in
diagnosing FTD in the target population  
To identify gaps in the evidence and where further research is required 
Methods 
Criteria for considering studies for this review
Types of studies 
Two main study designs are used when evaluating rCBF SPECT in the diagnosis of FTD: cross-sectional studies with a
case-control design and longitudinal or cohort studies with delayed verification of diagnosis (i.e. verification of FTD during a
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period of follow up). We expected that most of the study designs identified in this review would be case-control studies in
which rCBF SPECT was administered to a sample of people with a diagnosis of FTD and to a sample of people without FTD
(most likely with AD). We expected also to find some studies in which a cohort of people with unspecified dementia (i.e.
dementia of unknown subtype) were administered rCBF SPECT and then followed up for confirmation of the presence or
absence of FTD, either by clinical course or by neuropathological confirmation. Study participants were also likely to have
undergone other imaging investigations (e.g. CT or MRI) to help exclude other subtypes of dementia prior to study
recruitment. The reason for our expectation was that SPECT is an expensive and invasive test which uses a radiotracer.
Case-control studies are subject to considerable spectrum bias (Davis 2013). Prior to carrying out this work, we agreed that if
most of the studies identified were in this category, we would present the findings of these studies as the current best
evidence of the diagnostic accuracy of rCBF SPECT for FTD in a narrative review, with no meta-analysis in order to avoid a
biased summary estimate of accuracy. We would also highlight the limitations of the clinical implications of these findings. If
we identified any cohort studies of participants with unspecified dementia that received rCBF SPECT at baseline, we planned
to present the findings separately, with a meta-analysis if pooling was appropriate.
Settings
Due to the expense and technological expertise required, we expected the studies to be limited to secondary and tertiary
healthcare settings. Specialist memory clinics provide the most common source of participant recruitment to rCBF SPECT
studies. We expected such individuals to have been likely to have undergone neuropsychological testing and imaging
investigations prior to recruitment.
Participants
For case-control studies, we included all participants who had been recruited and clinically diagnosed with FTD (bvFTD,
PNFA or SD) or other dementia subtypes using standard clinical diagnostic criteria (see the Reference standards section).
For cohort studies, we included studies in which all participants with suspected dementia were administered rCBF SPECT at
baseline. We excluded studies with selected populations (e.g. post-stroke or those with Parkinson's disease) and studies of
participants with a secondary cause of cognitive impairment, namely current or a history of alcohol/drug abuse, central
nervous system trauma (e.g. subdural haematoma), tumour or infection.
Index tests
The use of rCBF SPECT in the characterisation of FTD is dependent on a chain of actions, all of which have the potential to
affect the quality of the data used for clinical reporting. A radiotracer is injected into an individual, followed by image
acquisition and reconstruction to produce a blood flow map. The blood flow map is interpreted by one or more clinicians with
the aim of identifying patterns representative of FTD (i.e. bilateral frontal hypoperfusion). Further computerised analysis may
then be carried out, typically the comparison of the blood flow map obtained with those in a database of control scans.
European Association of Nuclear Medicine (EANM) (Kapucu 2009) and Society of Nuclear Medicine (SNM) (Juni 2009)
guidelines for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals in the USA and Europe make detailed
recommendations which are summarised below.
Patient preparation: place the individuals in a quiet, dimly lit room, insert an intravenous cannula 10 to 15 minutes prior to
injection (no patient interaction within 5 minutes of injection)
Radiopharmaceutical preparation: use 99mTc-ECD or stabilised 99mTc-HMPAO
Data acquisition: detailed recommendations are made, notably concerning the use of multiple detector gamma cameras,
collimation and acquired counts
Image processing: general recommendations are made regarding reconstruction, corrections, reformatting of slice data
and semiquantitative evaluation
Interpretation criteria: relevant structural information from CT and MRI must be considered to help interpret the SPECT
scans. It is possible to standardise and analyse SPECT images by focusing on a particular region of interest, comparing
them to a normal database, or both.
Both the EANM and SNM guidelines state that single-detector systems (single-headed) should be used only if the scan time
is such that at least 5 million counts are detected. We did not exclude studies that used a single-headed system, but
evaluated them separately from studies that used a multiple-detector (multi-headed) system.
These guidelines provide a framework for the assessment of most of the technical aspects of published studies evaluating
the use of rCBF SPECT in the characterisation of FTD, with two important provisos. First, published reports do not generally
specify how they carried out the study in sufficient detail to allow a complete and impartial judgement of quality to be made.
Second, both sets of guidelines tentatively recommend that patient images are compared with those in control databases in
order to aid interpretation, but list "database issues" under "issues requiring further clarification". Furthermore, limited specific
recommendations are made regarding the demographic and technical aspects of control database comparisons. These
recommendations concern the need for age matching and use of the same type of camera and processing methods for both
controls and patients. We did not plan to discuss the relative advantages and disadvantages of different analysis methods.
No recommendations are made regarding how thresholds for a 'positive' rCBF SPECT scan should be set. It is probably the
case that more modern analysis methods utilising multivariate statistics, computationally intensive registration methods and
large multicentre control databases are likely to be more accurate than older methods. As both sets of guidelines are recent
and make no specific recommendations, we were cautious in making judgements in these areas.
Target conditions
The target condition was FTD, also referred to as frontotemporal lobar degeneration (FTLD). This included bvFTD, PNFA
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and SD.
Reference standards
We considered a diagnosis of FTD based on any of the following recognised diagnostic criteria as acceptable.
Lund-Manchester (Lund and Manchester Groups 1994)1.
Neary criteria (Neary 1998; Appendix 1)2.
National Institute of Neurological Disorders and Stroke (NINDS) criteria for FTD (McKhann 2001)3.
Histopathological diagnosis (Mackenzie 2010; Mackenzie 2011)4.
Presence of a genetic mutation known to be associated with FTD, including the microtubule-associated protein tau5.
(MAPT), progranulin (GRN), transactive response DNA-binding protein (TARDBP), valosin-containing protein (VCP
), chromosome 9 open-reading frame 72 (c9orf72) and charged multivesicular body protein 2B genes (Mahoney 2012).
We considered the diagnosis of 'controls' (i.e. non-FTD individuals) in case-control studies as acceptable if
standardised definitions of dementia subtypes (usually AD) were used. These included NINCDS-ADRDA (National
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related
Disorders Association) (McKhann 1984); Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (Mirra 1991
); NINDS-Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN) (Román 1993),
Alzheimer's Disease Diagnostic and Treatment Centers (ADDTC) (Chui 1992) and Cambridge Mental Disorders of
the Elderly Examination (CAMDEX) criteria (Hendrie 1988). In cohort studies, we accepted all-cause (unspecified)
dementia diagnosed using Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and
ICD-10 criteria (American Psychiatric Association 2013; WHO 2010).
Search methods for identification of studies 
The search strategies detailed in Appendix 2 utilised only two search concepts, keeping the search sensitive. The concepts
were (a) the index test and (b) in general and specific terms, the condition of interest.
Electronic searches 
The most recent search for this review was performed on 1 June 2013. We searched MEDLINE (Ovid SP) (1950-01June
2013), EMBASE (Ovid SP) (1980-31 May 2013), BIOSIS (Ovid SP) (1926-31 May 2013), PsycINFO (Ovid SP) (1806-Week 4
May 2013), CINAHL (EBSCO) (1950-May 2013) and LILACS (Bireme) and the Web of Science Core Collection (ISI Web of
Science) (1945-31 May 2013), including Conference Proceedings Citation Index (Thomson Reuters Web of Science). See
Appendix 2 for the search strategies.  We used standardised database subject headings such as MeSH (Medical
subject heading) terms (in MEDLINE) and Emtree (in EMBASE) and other standardised headings (controlled
vocabulary) in other databases, as appropriate. We did not use search filters designed to retrieve diagnostic test
accuracy studies (collections of terms aimed at reducing the number needed to screen by filtering out irrelevant
records and retaining only those that are relevant) as a method to restrict the search because available filters have
not yet proved sensitive enough for systematic review searches (Whiting 2011). We also requested a search of the Cochrane
Register of Diagnostic Test Accuracy Studies. A single researcher with extensive experience of systematic reviewing
performed the searches. We did not restrict studies based on setting or language.
Searching other resources 
We checked the reference lists of all relevant papers for additional studies.
We also searched:
The MEDION Database (Universities of Maastricht and Leuven, www.mediondatabase.nl);
DARE (Database of Abstracts of Reviews of Effects, via the Cochrane Library);
HTA (Health Technology Assessments) database (via the Cochrane Library);
ARIF (Aggressive Research Intelligence Facility, www.arif.bham.ac.uk).
We used the related articles feature in PubMed to search for additional studies. We tracked key studies in citation
databases such as Science Citation Index and Scopus to ascertain any further relevant studies.  We identified ‘grey’
literature, mainly in the form of conference abstracts, through the Web of Science Core Collection, including
Conference Proceedings Citation Index and EMBASE.  We aimed to access theses or dissertations from institutions
known to be involved in prospective dementia studies. We also attempted to contact researchers involved in
relevant studies who might have applicable but unpublished data. We did not perform handsearching as evidence of
the benefits of handsearching is uncertain. The findings of a recent study investigating handsearching as a method
for identifying diagnostic test accuracy studies suggested little additional benefit for handsearching above a robust
initial search strategy in a well-indexed and clearly defined subject area (Glanville 2010). 
We did not search ALOIS for this review as the DTA register in ALOIS is geared towards neuropsychological tests rather
than biomarkers or imaging, and therefore was not thought to be applicable to this study.
Data collection and analysis 
Selection of studies 
Study authors (ANS, EJC, NS, SC, HAA) screened the titles and abstracts of identified studies. Subsequently, we
located the full text for each potentially eligible study identified by the search. At least two of three study authors (CJ,
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EJC, HAA) independently evaluated these papers for inclusion or exclusion, after assessment of the sampling frame of
each study. We resolved disagreements by discussion with a third author (SC, NS). We then created a Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Moher 2009) showing details of the
study selection process.
Data extraction and management
We extracted data on study characteristics into a study-specific form, including data for the assessment of methodological
quality and data for the investigation of heterogeneity, as described in Appendix 3. We piloted the form using two of the
included studies. 
Two review authors (HAA, NS) extracted data from the form. We created 2 x 2 tables by dichotomising the results of
rCBF SPECT ('FTD pattern present' or 'FTD pattern absent') and cross-tabulating them against the results of the
reference standard ('FTD present' (disease positive) or 'FTD absent' (disease negative)) used in each study (Table 1). We
entered the 2 x 2 tables directly into Review Manager 2013.
Assessment of methodological quality
We assessed the methodological quality of each study using the QUADAS-2 (Quality Assessment of Diagnostic
Accuracy Studies) tool (Whiting 2011). The tool is made up of four domains: participant selection; index test;
reference standard; patient flow (Appendix 4). We assessed each domain in terms of risk of bias, with the first three domains
also assessed in terms of applicability concerns. Operational definitions describing our application of the QUADAS-2 tool are
detailed in Appendix 5. We produced a narrative summary describing numbers of studies that were found to have
high/low/unclear risk of bias as well as concerns regarding applicability.
In addition to the QUADAS-2 tool, we assessed the index test using the following broad criteria with regard to study quality.
Visual rating
Was rating carried out by multiple experts blinded to the clinical and/or pathological status of the patient?
Did the raters use well-defined criteria for assessing scans? Are these criteria explained in sufficient detail to reproduce
independently?
Semiquantitative evaluation
If quantitative maps were visually assessed then the two criteria above are applicable
Ideally, scans should be assessed with and without quantitative analysis
Ideally there should be an explanation of the methods used to derive any thresholds used in the computation of
quantitative results and the effects of threshold setting on sensitivity and specificity
If normal database comparisons are used, details should be given of normal screening procedures and to what extent
demographic matching (e.g. age, sex, education) was achieved
Statistical analysis and data synthesis
We evaluated test accuracy according to target condition and SPECT technology (single-detector and multiple-detector
camera SPECT). We also considered case-control and cohort studies separately. We performed exploratory analyses by
plotting estimates of sensitivity and specificity from each study on forest plots and in receiver operating characteristic (ROC)
space. We planned to perform meta-analyses by using the bivariate model to obtain average estimates of sensitivity and
specificity. However, we were unable to perform meta-analyses due to heterogeneity in study design, participant selection,
the nature of the data available for analyses, reference standard and SPECT methodology.
Investigations of heterogeneity
We planned to investigate the effect of the following factors.
Index test: different image analysis techniques and thresholds; technical features of scanning (e.g. camera resolution,
scatter correction, total counts acquired); operator characteristics (e.g. training)
Target disorder: reference standard used; operationalisation of these classifications (e.g. individual
clinician/algorithm/consensus group); stage and severity of dementia
Target population: sociodemographic characteristics (age, sex, education); clinical settings; other characteristics (e.g.
family history of motor neurone disease)
Study quality: blinding; time between performing rCBF SPECT and reference standard. For cohort (delayed-verification)
studies we also planned to investigate duration of follow up and loss of participants due to withdrawals and those lost to
follow up
We investigated heterogeneity through visual examination of forest plots of sensitivities and specificities and summary
receiver operating characteristic (SROC) plots. The main sources of heterogeneity were likely to be the criteria used to define
the positivity of rCBF SPECT, reference standards, patient sampling and aspects of study quality (particularly inadequate
blinding). We were not able to formally assess the effect of each potential source of heterogeneity by using meta-regression
as planned because we did not perform meta-analyses.
Sensitivity analyses
We did not conduct sensitivity analyses as planned due to insufficient data and because we did not perform meta-analyses.
Assessment of reporting bias
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We did not investigate reporting bias because of current uncertainty about how it operates in test accuracy studies and the
inadequacy of existing analytical tools such as funnel plots.
Results 
Results of the search
We identified a total of 11,846 records through database searches. After de-duplication, a small team of assessors
(HAA, EJC, CJ) performed a first assessment of the remaining records. The flow diagram (Figure 1 ) shows the flow of
studies through the screening and selection process. In total, we assessed 116 studies (92 full-text papers and 24 abstracts)
for eligibility. We included 11 studies and excluded 105 studies. We were unable to extract data for creating 2 x 2 tables from
31 studies (see Characteristics of excluded studies table), three studies were multiple publications and, for ten studies,
published abstracts/posters only were available. We excluded the remaining 61 studies because they did not meet the
inclusion criteria: i) participants: not those with suspected dementia or not those clinically diagnosed with FTD and other
forms of dementia (n = 18); ii) type of study: a review, a book chapter or an editorial letter, exploratory or pathological study
(n = 24); iii) index test: not rCBF SPECT using 99mTc-HMPAO or 99mTc-ECD tracers (n = 15); iv) papers
evaluating rCBF SPECT scan technique (n = 4). We found no additional studies through reference checking,
though we obtained usable data for three studies by contacting the authors of the studies (Boutoleau-Bretonniere 2012; 
Nagao 2004; Rollin-Sillaire 2012).
Characteristics of included studies
We provide details of the 11 included studies, including 1117 participants (including 299 FTD cases) in the Characteristics of
included studies table; we summarise key characteristics of the 11 studies in Table 2. All the studies assessed rCBF
SPECT for differentiating FTD from AD, and five of the studies also assessed rCBF SPECT for differentiating FTD
from non-FTD. Four studies (Launes 1991; Pickut 1997; Read 1995; Talbot 1998) were published more than 15 years ago.
The remaining seven studies were published in the last 10 years (2004 to 2012). Eight of the studies were conducted in
Europe (three in France, two in the UK, one in Finland, one in Belgium and one in Greece), two in the USA and one in Japan.
Study sizes ranged from 27 to 363 participants. A range of populations was assessed, with the youngest study
population aged between 42 and 69 years (Read 1995), and the oldest study population aged 70.0 ± 9.0 years
(mean±standard deviation) (Pickut 1997). APOE e4 (apolipoprotein) carrier status and years of education were poorly
reported. Participants were mainly outpatients recruited from University clinics (n = 7) or from a General Hospital
memory clinic (n = 1). One study recruited participants from a tertiary referral centre (McNeill 2007). Horn 2007 was a
multicentre study and recruited inpatients from a number of hospitals. Lipton 2004 did not report source of recruitment.
Two studies did not specify the criteria used for clinical diagnosis (Horn 2007; Pickut 1997), four used the Neary
criteria (Boutoleau-Bretonniere 2012; Launes 1991; Nagao 2004; Valotassiou 2012), one used the Lund-Manchester
Criteria (Talbot 1998), and four used histopathological confirmation (Lipton 2004; McNeill 2007; Read 1995; Rollin-Sillaire
2012). Interpretation of SPECT images varied between studies (Table 2): six studies used combined visual and
semiquantitative evaluation whereas the remaining five studies used only visual inspection.
Eight studies visually assessed SPECT images but details of the process were poorly reported. Three studies (McNeill 2007; 
Read 1995; Talbot 1998) used one rater, with one (McNeill 2007) using a second rater to validate the assessment.
Three studies (Boutoleau-Bretonniere 2012; Pickut 1997; Rollin-Sillaire 2012) used two experts, and one (Horn 2007)
used four. One study (Launes 1991) stated that images were "assessed visually" and one (Lipton 2004) used
information from past reports. Only one study reported inter-rater reliability (McNeill 2007).
All 11 studies evaluated brain regions that were expected to be affected by FTD. In these terms, all studies involved
frontal and/or temporal lobes. Two studies (Lipton 2004; McNeill 2007) also involved parietal and occipital lobes
in their evaluations. One study (Valotassiou 2012) used a range of Broadmann areas (BAs).
Methodological quality of included studies
We present our judgements about each methodological quality item for each included study in the Characteristics of included
studies table and Figure 2. We summarise the overall methodological quality of the studies in Figure 3.
In the participant selection domain, we considered six studies to be at high risk of bias (Horn 2007; Lipton 2004; McNeill
2007; Nagao 2004; Pickut 1997; Valotassiou 2012), and five studies to be at unclear risk of bias because of poor
reporting (Boutoleau-Bretonniere 2012; Launes 1991; Read 1995; Rollin-Sillaire 2012; Talbot 1998).
In the index test domain, we considered eight studies to be at high risk of bias because the threshold used was not
prespecified and the index test results were interpreted with knowledge of the results of the reference standard, or a
single-headed camera was used (see the Technological considerations section below), or it was poorly reported (Horn 2007; 
Launes 1991; Lipton 2004; McNeill 2007; Nagao 2004; Pickut 1997; Talbot 1998; Valotassiou 2012). We judged Read 1995
to be at unclear risk of bias because the SPECT methodology was unclear. We judged the remaining two studies (
Boutoleau-Bretonniere 2012; Rollin-Sillaire 2012) to be at low risk of bias.
In the reference standard domain, we judged the majority of studies (8/11) to be at low risk of bias. We considered Horn
2007 and Pickut 1997 to be at high risk of bias because the reference standard was not specified and it was not clear
whether the reference standard results were interpreted without the knowledge of the index test. We judged Talbot 1998 to
be at unclear risk of bias because it was not clear whether the assessor who interpreted the results of the reference standard
was blind to the results of the index test.
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In the flow and timing domain, we considered Lipton 2004 to be at high risk of bias because the index test was not
performed in 4 of 10 participants with FTD. We considered three studies (Boutoleau-Bretonniere 2012; Talbot 1998; 
Valotassiou 2012) to be at unclear risk of bias because not all participants were included in the analysis. We considered the
remaining seven studies to be at low risk of bias.
Regarding the assessment of applicability concerns, our concern that the included participants and setting, the conduct and
interpretation of the index test, and the target condition (as defined by the reference standard) did not match the review
question was low for the majority of the studies (8/11). We considered concerns regarding applicability to be unclear for Horn
2007 in all three domains, for Pickut 1997 in the reference standard domain and for Lipton 2004 in the participant selection
domain.
It should be noted that our low concern about the applicability of the three domains mentioned above was based on the
inclusion criteria set in the review. Considering the wide variation in study characteristics, we consider that these judgements
about applicability may be overstated. In particular, we consider that the findings from the case-control studies are unlikely to
be directly applicable to our target population of memory clinic attendees, despite recruitment from secondary and tertiary
settings. Three of the studies were carried out in memory clinic cohorts but two of these used single-headed camera SPECT
which is no longer used, and therefore not applicable to current practice.
Technological considerations
After technological review of the methods, we found three studies (Launes 1991; McNeill 2007; Talbot 1998) to have used a
single-headed system. From the acquisition details described in the studies by McNeill 2007 and Talbot 1998, we estimated
that 2 million counts were acquired for each participant. Launes 1991 did not provide sufficient details for the direct
estimation of acquired counts; however, we estimated that a total acquisition time of around 45 minutes would be
required to collect the minimum of 5 million counts recommended by the EANM (Kapucu 2009) and SNM (Juni 2009)
guidelines. None of these studies used any form of quantitative image analysis. Read 1995 described the use of two SPECT
cameras and the protocol followed is unlikely to represent that seen in standard clinical practice.
In our original protocol we described both the EANM and SNM guidelines but felt that, as these guidelines make only general
recommendations, we should exercise caution in making judgements about which camera type to use. As such we have not
excluded papers that used a single-headed system from the review but report their findings separately.
Findings
We did not perform meta-analyses because of substantial differences between studies as outlined above. We therefore
present a narrative summary of the studies.
rCBF SPECT for differentiating FTD from non-FTD
Five studies reported the accuracy of rCBF SPECT for distinguishing FTD from non-FTD (Figure 4; Figure 5). All
the studies used a cohort design; three were prospective (Boutoleau-Bretonniere 2012; Launes 1991; Talbot 1998) and
two were retrospective (with histopathological confirmation) (Read 1995; Rollin-Sillaire 2012). Read 1995 and Rollin-Sillaire
2012 both required a SPECT scan at baseline as part of the inclusion criteria and so we consider that there is potential for
selection bias.
Two of the three prospective studies used single-headed camera SPECT and reported similar findings. Launes 1991
reported a sensitivity of 0.40 (95% CI 0.05 to 0.85) and a specificity of 0.95 (95% CI 0.90 to 0.98). The sensitivity and
specificity reported by Talbot 1998 were 0.36 (95% CI 0.24 to 0.50) and 0.92 (95% CI 0.88 to 0.95), respectively. The
remaining three studies used multiple-headed camera SPECT and reported sensitivities of between 0.73 and 1.00, and
specificities of between 0.80 and 1.00.
rCBF SPECT for differential diagnosis of FTD from AD
Six case-control studies and five cohort studies reported the accuracy of rCBF SPECT for distinguishing FTD from AD
(Figure 6; Figure 7). Of the 11 studies, six did not predefine a threshold for determining whether the SPECT image
suggested a diagnosis of FTD or AD. Three of the six studies (Pickut 1997; Lipton 2004; Talbot 1998) compared the
ability of different combinations of perfusion patterns to correctly assign participants into either an FTD or AD group
(based on clinical diagnosis or histopathology). The remaining three studies (Horn 2007; Nagao 2004; Valotassiou 2012
) evaluated computer-defined quantitative imaging to differentiate FTD from other participants with dementia. Of
the five studies that predefined thresholds (Boutoleau-Bretonniere 2012; Launes 1991; McNeill 2007; Read 1995; Rollin-
Sillaire 2012), three (McNeill 2007; Read 1995; Rollin-Sillaire 2012) compared SPECT image reporting to histopathologically
confirmed diagnoses.
Three studies (Launes 1991; McNeill 2007; Talbot 1998) used single-headed camera SPECT. Two of the studies (Launes
1991; Talbot 1998) were prospective cohort studies in people with dementia attending a memory clinic. Both studies
reported much lower sensitivity (0.40 and 0.46, respectively) and higher specificity (0.97 and 0.96, respectively) than
the third study (McNeill 2007) which was a case-control study that reported a sensitivity of 0.80 and specificity of
0.61. Eight studies used multiple-headed camera SPECT. Of these, five studies used a case-control design and
reported sensitivities of between 0.52 and 1.00, and specificities of between 0.41 and 0.86. The remaining three
studies used a cohort design; one was a prospective study (Boutoleau-Bretonniere 2012) in a selected memory clinic
population of 'clinically ambiguous' dementias (i.e. dementias that had not been diagnosed by other means (this is the
most common use of SPECT in a clinical setting)), and two were retrospective (Read 1995; Rollin-Sillaire 2012). The three
studies reported sensitivities of between 0.73 and 1.00, and specificities of between 0.94 and 1.00.
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rCBF SPECT for differential diagnosis of FTD from VaD
One prospective study evaluated the differentiation of FTD from VaD, with a resultant sensitivity of 73% and
specificity of 94% (Boutoleau-Bretonniere 2012). Two single-headed camera rCBF SPECT studies (Launes 1991; Talbot
1998) evaluated whether rCBF SPECT could discriminate between FTD and VaD, and reported sensitivities of 40% to 46%
and specificities of 73% to 94%.
Investigation of heterogeneity
We were unable to formally investigate heterogeneity because we did not perform meta-analyses. As can be
seen from above, the studies differed widely in design, with several potential sources of heterogeneity. In the
Methods section (Investigations of heterogeneity) we outlined four sources: index test, target condition, population and study
quality.
The application and interpretation of rCBF SPECT is most likely to represent the largest source of variability between the
studies. Studies differed in how rCBF SPECT images were assessed and classified as 'positive' or 'negative' for the
presence of FTD. Diagnoses were made based on a prespecified pattern of cerebral hypoperfusion (threshold) (e.g. frontal
with or without temporal hypoperfusion), regional scores of severity or through evaluation of historical reports. In some
studies no 'threshold' for a positive scan was prespecified. rCBF SPECT images were analysed visually by single or multiple
raters or quantitatively using computer programs and could be derived from either one or a variety of different scanners.
Similarly there was variation in how FTD was diagnosed clinically. Some studies used the 'gold standard' of histopathology
whereas others used clinical diagnosis using either the Neary or Lund-Manchester criteria. It is likely that the severity of
dementia also varied between studies. However, information on neuropsychological performance was not readily available.
With regards to the study populations, participants were recruited through a variety of means, including prospective
recruitment during clinic visits, selection from clinical records or research databases, and retrospective selection based on
post-mortem findings. Some studies compared only individuals with FTD with those with AD, whereas others evaluated rCBF
SPECT imaging in cohorts of 'mixed' dementias.
Unfortunately we were not able to formally assess the effect of each potential source of heterogeneity due to the small
number of studies available for inclusion in the review.
Figure 5 and Figure 7 show the variation in the sensitivity and specificity of rCBF SPECT for differentiating FTD from non-
FTD or AD by study design and type of camera system. However, each study should be considered individually using the
details given in our narrative, Table 2 and the Characteristics of included studies table.
Discussion 
The literature on the use of rCBF SPECT for discriminating FTD from other dementias is dominated by case-control studies,
with a paucity of well planned prospective cohort studies. This made it difficult to obtain an average sensitivity and specificity
for differentiating FTD from other dementias. As a result we found a wide range of sensitivities and specificities, with
sensitivities ranging from as low as 36% in single-headed camera studies to as high as 100% in multiple-headed camera
studies. The specificity for the same group ranged between 41% and 100%.
Case-control studies and retrospective cohort studies do not reflect normal clinical practice and are known to produce
overestimates of specificity and sensitivity. However, the prospective cohort studies were also limited by methodological
considerations. In particular, two of these studies were performed using single-headed cameras that have gradually been
replaced in clinical practice by multiple-headed gamma cameras. The single-headed cameras are generally likely to have
lower resolution and provide less uniform pictures than those of the multiple-headed cameras, and are compromised by an
inability to boost their performance unlike that of the multiple-headed forms. As such their findings are likely to be less
accurate than those obtained using currently recommended techniques.
In addition to differences in study design, our findings demonstrate that the available literature on rCBF SPECT for
detecting FTD is very variable in terms of type and severity of dementia, reference standards and rCBF SPECT
methodology. The variation between studies is partly due to the wide range of stated objectives. Some aimed to
identify patterns of cerebral hypoperfusion suggestive of FTD (Lipton 2004; Pickut 1997), others sought to develop
new quantitative techniques to aid image analysis (Nagao 2004; Valotassiou 2012), whereas only a small number
assessed whether a predefined pattern of cerebral blood flow could diagnose FTD from a cohort of 'mixed
dementia' participants (Boutoleau-Bretonniere 2012; Launes 1991; Talbot 1998). Differences in reference
standards used will also have contributed a source of heterogeneity, with several studies using histopathological
confirmation (considered to be the gold standard for FTD diagnosis) whereas others used variations of the Lund-
Manchester and Neary criteria. As previously discussed, these clinical criteria have limitations in terms of how
accurately a diagnosis of FTD can be made, and have led to the production of revised criteria with improved
accuracy of diagnosis (Rascovsky 2011).
Our review has demonstrated a wide variation in terms of participant recruitment and data interpretation. On the
whole, the amount of detail provided regarding participant identification and assessment was limited. In some studies
participant recruitment was achieved from 'chart review' (McNeill 2007) or the searching of 'databases' (Horn 2007; Lipton
2004; Rollin-Sillaire 2012) or 'data files' (Nagao 2004) for individuals who may have had clinical or
histopathological diagnoses of dementia and previous SPECT imaging. Still others recruited participants
prospectively and consecutively (Boutoleau-Bretonniere 2012; Launes 1991; Talbot 1998). In addition, not all studies
reported the severity of cognitive impairment in their participants, with neuropsychological assessments used mainly for
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diagnostic rather than descriptive purposes. It is possible that some SPECT scans may have been carried out early in the
disease process whilst others may have been imaged much later, influencing the pattern of cerebral hypoperfusion seen due
to changes in brain structure and function related to the underlying neurodegenerative process. Recruitment of participants
from mainly secondary or tertiary sources means that the generalisation of these results to the general population is likely to
be misleading.
In terms of SPECT scan analysis, there was variation in whether scans were interpreted by one or multiple raters,
or whether a previous clinical SPECT report was used. Two studies used consensus reporting, a method not
commonly used in day-to-day practice (Boutoleau-Bretonniere 2012; Pickut 1997). Of all the studies, only one
reported an inter-rater reliability measurement with a kappa of 0.48 (McNeill 2007). This study was from the single-headed
camera group. Horn 2007 suggested that the correct classification of images depended on both the experience of the
reporter and also on whether the images had come from their own centre. Reproducibility in image reporting is an essential
aspect in assessing the utility of this tool, where scans are often reported qualitatively but not quantitatively. It is likely that
lack of standardisation in how scans are reported, and questionable reproducibility will lead to less accurate results.
Of all the available studies, Boutoleau-Bretonniere 2012 most closely mirrors both the participant population and methods
commonly seen in clinical practice. Due to the small number of studies, differing protocols and limited applicability to
everyday practice it is difficult to make a recommendation on the use of rCBF SPECT in clinical practice based on these
results. More prospective cohort studies with delayed verification would be helpful, particularly if verification was also
confirmed by histopathological diagnosis.
Summary of main results
This review demonstrates that the currently available literature does not clearly answer the question of whether rCBF SPECT
can differentiate FTD from AD and other dementias. The 11 studies included in this review varied widely in terms of their
study design (case-control or cohort), technological methodology (single- or multiple-headed cameras, in how and when
thresholds for a scan 'positive' for FTD were determined, how scans were reported and whether this was qualitative or
quantitative) and reference standard (clinical or histopathological). The studies differed in their objectives; for example,
whether they sought to identify a pattern of cerebral perfusion characteristic of FTD, or aimed to test whether a predefined
pattern of cerebral perfusion could correctly identify FTD. These factors, along with the wide range of sensitivities and
specificities reported makes the value of rCBF SPECT in FTD uncertain.
Strengths and weaknesses of the review
One study (Boutoleau-Bretonniere 2012) most closely mirrored the patient population and study design appropriate to
evaluate rCBF in clinical practice. In addition, four of the included studies (Lipton 2004; McNeill 2007; Read 1995; Rollin-
Sillaire 2012) were conducted using the gold standard of histopathological diagnosis, which allows a definitive diagnosis to
be given and, therefore, allows greater certainty in assessing the accuracy of rCBF SPECT for identifying FTD. Due to the
small number of studies designed specifically to address this question, as well as confounding factors in terms of scan
acquisition and analysis, it is difficult to draw conclusions regarding how rCBF SPECT compares to clinical diagnosis when
histopathological confirmation is available. More studies using histopathology as a reference standard would be helpful.
A weakness of this review is the limited number and variability of the different studies available for review. As we have
illustrated, a wide range of recruitment techniques, both retrospective and prospective studies, different cohort composition
and sizes have been reported.
It must be noted that several papers from which we extracted data for this review did not have our central objective as their
primary aim. Furthermore, we have not been able to assess the impact that differing methods of analysis (qualitative - single-
/multirater - or quantitative) have on sensitivity and specificity, and it is not clear whether the accuracy of the diagnosis
depends on the patterns of hypometabolism per se or on the measurement or interpretation of this pattern.
These results are unlikely to be generalisable to a memory clinic setting. The majority of studies evaluated the use of rCBF
SPECT in isolation to diagnose FTD, but this does not represent how this technique is used in clinical practice. We have
been unable to answer whether, when this technique is used within a clinical context as suggested by Rascovsky 2011, the
sensitivity and specificity of a diagnosis of FTD improves. Our review suggests that there is inadequate literature available at
present to address this question.
Applicability of findings to the review question
Our findings highlight the need for further studies in this area. In particular, protocols should be standardised, study
populations well described, thresholds for 'abnormal' scans predefined and clear details given on how scans are analysed.
Authors' conclusions 
Implications for practice 
At present we can not make any recommendations for the use of rCBF SPECT in the diagnosis of FTD on the basis of our
findings.
Implications for research 
Further research using predetermined patterns of cerebral hypoperfusion in large prospectively followed cohorts of
individuals with mixed dementia is required to evaluate the sensitivity and specificity of rCBF SPECT for detecting FTD. It
would be useful to compare the diagnostic accuracy of a combination of clinical information and rCBF SPECT to a
combination of clinical information and another neuroimaging modality (such as MRI). For clinically applicable research, a
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cohort of memory clinic patients could be selected for SPECT on the basis of their clinical history and equivocal
neuroimaging. Delayed verification could be used to confirm the diagnosis at a later date through either future clinical
evaluation or post mortem. It is essential that measurements of intra- and inter-rater reliability are reported to allow a
judgement to be made on how reproducible these findings may be in everyday practice. Standardisation of the interpretation
of images between centres would also be very useful.
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A. Risk of Bias
Patient Sampling
Patients attending the Neurological Memory Center at
Nantes University Hospital were enrolled prospectively
over a period of 36 months (2004 to 2007) to a
longitudinal study. The sampling procedure not
reported.
The exclusion criteria included: major depressive
disorders, probable AD dementia, FTD, VaD, LBD,
Parkinson's disease, rapidly progressing dementia,
neoplastic, inflammatory, infectious or metabolic
disease, and contraindications to SPECT or MRI
imaging.
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
Ninety-one participants with clinically ambiguous dementia
(CAD) were screened. Fourteen participants did not fulfil
inclusion criteria and eight refused to participate in the
study.
69 participants were recruited after
neuropsychological assessment, CSF sampling, MRI
and SPECT and prospectively followed up. At
baseline, patients were examined both by a
neurologist and a neuropsychologist for eligibility
according to the CAD criteria: 1) dementia according
to DSM-IV criteria; 2) cognitive changes of moderate
severity (MMSE ≥18); 3) clinical symptoms at
inclusion not fulfilling existing criteria for
frontotemporal dementia (FTD) (Neary 1998),
vascular dementia (Román 1993), progressive
supranuclear palsy/corticobasal degeneration
spectrum (Gibb 1989; Litvan 1996), Parkinson's
disease, and Lewy body disease (Hughes 2001; McKeith
2005), 4) presence of ≥1 atypical feature for AD listed in
criteria III to V of NINCDS-ADRDA criteria (i.e. early and
prominent neuropsychiatric symptoms, early gait
disturbances, focal neurological findings, systemic or brain
disorder sufficient to produce dementia which is not
considered to be the cause of the dementia). Demographic
data reported on 60 participants who had follow-up
assessment:
Gender: 23 F, 37 M (FTD: 4 F; 7 M; AD: 9 F, 9 M; VaD: 3
F; 5 M)
Age (mean±SD years): 63.9 ± 9.4 (FTD: 68.6 ± 5.4; AD:
65.2 ± 9.4; VaD: 62.6 ± 9.0)
MMSE (mean±SD): 22.3 ± 3.5 (FTD: 22.5 ± 3.6; AD: 21.1
± 3.8; VaD: 23.6 ± 1.9)
Education: 23/60 graduated (FTD: 3/11, AD: 9/9 and VaD:
2/8 graduated)
Sources of referral: patients were referred by neurologists
or general practitioners
Sources of recruitment: Neurological Memory Center,
University Hospital, Nantes, France
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
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Index tests
99mTc-HMPAO SPECT
99mTc-HMPAO fixation was analysed regionally for frontal, parietal, temporal and occipital regions on
the left and right. According to the pattern of 99mTc-HMPAO fixation, results were classified in four
categories:
hypoperfusion of the AD type (temporoparietal hypoperfusion, whatever the perfusion of the frontal
lobes)
hypoperfusion of the FTD type (frontal ± temporal hypoperfusion, no posterior defect)
hypoperfusion of another type
normal SPECT
Threshold: prespecified; visual interpretation of the SPECT images
Two of the authors that were not implicated in patient care and blind to all clinical data analysed
SPECT
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTD (differential diagnosis
of FTD versus 1. AD dementia and 2. VaD
dementia)
Reference standards: Neary 1998.
The clinical diagnosis of Alzheimer’s
disease dementia and VaD dementia
were established by the NINCDS-
ADRDA (McKeith 2005) and NINDS-
AIREN (Román 1993) criteria, respectively.
Clinicians were unaware of SPECT pattern
(p325)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow up: 24 months
At baseline 69 participants
At follow up (table 3, p328 & information from the author):
60 participants were assessed by neuropsychological tests
and MRI and included in analysis
11 FTD: 8 FTD type SPECT (TP = 8); 3 AD type (FN = 3)
18 AD: 1 FTD type SPECT (FP = 1); 17 AD type (TN = 17)
8 VD: 2 FTD type SPECT (FP = 2); 3 AD type and 2 ‘other’
(TN = 6)
4 other dementia: 1 AD type + 3 ‘other’ (TN = 4)
12 unclassified: 4 with FTD type SPECT (FP = 4); 8 non-
FTD type SPECT (TN = 8)
7 Psych: 3 with FTD type SPECT (FP=3); 4 non- FTD type
SPECT (TN = 4)
1) SPECT FTD type pattern indicative of FTD (N = 60)
FTD = 11 (disease positive); non-FTD = 49 (disease
negative)
TP = 8, FP = 10, FN = 3, TN = 39; Sensitivity = 73%;
Specificity = 80% (calculated in RevMan5)
2) FTD vs AD (N = 29)
FTD = 11 (disease positive); AD = 18 (disease negative)
TP = 8, FP = 1, FN = 3, TN = 17; Sensitivity = 73%;
Specificity = 94% (calculated in RevMan5)
3) FTD vs VaD (N = 19)
FTD = 11 (disease positive); VaD = 8 (disease negative)
TP = 8, FP = 2, FN = 3, TN = 6; Sensitivity = 73%;
Specificity = 75% (calculated in RevMan5)
Lost to follow up: Nine patients withdrew from the study (6
were lost to follow up and 3 died)
All patients that had a follow-up assessment were included
in the analysis
Was there an appropriate interval between index test and
reference standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes The trial investigators were contacted; they provided some requested data tor the 2 x 2
table to be completed; email from Dr Boutoleau-Bretonniere on 25/3/14
 
Horn 2007
Patient Selection
A. Risk of Bias
Patient Sampling
Retrospective study of 173 patients from a
database
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
173 participants: 91 FTD and 82 AD. Each diagnosis was
established and retrospectively verified by a neurologist on
the basis of clinical symptoms, neuropsychological tests
and follow up. No further details. The widely used
reference standards for FTD and the standardised criteria
for AD dementia not reported
Demographic data not reported
Sources of recruitment: a number of different French
hospitals (Paris, Toulouse, Nice, Rennes, Nantes, Rouen,
Saint Etienne and Marseille)
Are there concerns that the included patients and setting do not
match the review question? Unclear
Index Test
Index tests
3D Tc-99m ECD (ethyl cysteinate diethylester) SPECT
There are obviously some differences between SPECT images caused by different cameras and
reconstruction methods
Threshold: visual inspection against a classifier; not prespecified: the best performances are obtained
for 8 PLS components and intensity normalisation based on the whole cortex, 0.5 probability threshold
for classifying data (table 1, p1338)
The images were reported by four experts, nuclear physicians with a high experience in SPECT
images, blind to all clinical data. The images were displayed according to their daily practice. In
addition, they were asked to give a probability-like diagnosis so that their doubts may be recorded. The
physicians seem to favour the detection of AD to the detriment of FTD: the 0.5 thresholds reveals
predominance of sensitivity over specificity. It can be noticed that AD has a higher prevalence than
FTD in their daily practice, leading them to biased diagnosis toward the most frequent disease. The
images were acquired in different hospitals with different cameras, and had undergone different
reconstruction methods. As a general experience, physicians found it more difficult to diagnose the
images from centres other than their own. As a matter of fact, their performances are higher for the
images coming from their own centre
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTD dementia (differential diagnosis of
FTD versus AD dementia)
Reference standard: not specified. Both the FTD dementia
and AD dementia were established and retrospectively
verified by a neurologist on the basis of clinical symptoms,
neuropsychological tests and follow up
Unclear whether the reference standard results were
interpreted without knowledge of the results of the index
test
Is the reference standards likely to correctly classify the target
condition? Unclear
Were the reference standard results interpreted without
knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation
have introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
The Interval between SPECT and clinical
assessment not reported. However, timing is
not applicable as cross-sectional. A delay is
unlikely to introduce bias as the condition of
dementia is irreversible
FTD vs AD (Table 1, p1338)
N = 173; n = 91 FTD (disease positive); n =
82 AD (disease negative)
TP = 77; FP = 15; FN = 14; TN = 67
Sensitivity = 85%; Specificity = 82%
Was there an appropriate interval between index test and reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Launes 1991
Patient Selection
A. Risk of Bias
Patient Sampling
160 consecutively imaged elderly patients with
suspected dementia from the hospital’s memory
disorder clinic were recruited
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
160 participants were included in the study. A
number of patients with dementia was 98 (Table
4, p762).
Demographic data on 5 FTD; 36 AD; 33 VaD
(MID: multi-infarct dementia); 32 SPEC (specific
causes of dementia)
Gender: FTD: 2 F; 3 M; AD: 25 F,11 M; VaD: 24
F; 9 M; SPEC: 16 F, 16 M
Age (mean±SD years): FTD: 66.0 ± 5.1; AD:
64.9 ± 8.1; VaD: 68.0 ± 7.9; SPEC: 58.4 ± 12.0
MMSE: not reported
Education: not reported
Duration of disease (mean±SD years): FTD: 3.2
± 1.5; AD: 2.8 ± 2.0; VaD: 3.2 ± 2.0; SPEC: 2.0
± 3.1
Sources of referral: not reported
Sources of recruitment: memory disorder clinic,
Helsinki University Central Hospital, Finland
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
99mTc-HMPAO SPECT
370 to 600 MBq dose was used. Data acquisition was started 2 to 5 min after the injection. SPECT
images were classified into five rCBF patterns:
FTD pattern: bilateral frontal or frontotemporal area of hypoperfusion
AD pattern: bilateral posterior parieto-temporal or parieto-temporo-occipital hypoperfusion
MID pattern: single large defect or multiple perfusion defects but no bilateral posterior parieto-
temporal hypoperfusion
Abnormal but unclassified
Normal
As the perfusion defects are not known to be preferentially located in any particular brain areas in MID
and a number of other dementing conditions, in contrast to AD and FTD, the rCBF was not semi-
quantified (e.g. by calculating cortical/cerebral count density ratios); therefore, the rCBF patterns on
the SPECT scans were interpreted only visually.
Threshold: prespecified; rCBF patterns on the SPECT scans were interpreted visually and without
knowledge of the clinical diagnosis. However, a single-headed camera was used with no extended
acquisition. Image analysis was not performed. This is against the EANM guidelines and would
represent an obsolete clinical service.
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTD dementia (differential
diagnosis of FTD vs 1. AD dementia, 2. VaD
(MID))
Reference standards: the Neary 1998
criteria. The clinical diagnosis of
Alzheimer’s disease dementia and
VaD (MID) dementia were
established by the NINCDS-ADRDA (
McKeith 2005) and DSM-III-R criteria,
respectively.
The SPECT results were unknown to the
clinicians
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Interval between SPECT and clinical assessment
not reported. However, timing is not applicable as
cross-sectional
A delay is unlikely to introduce bias as the
condition of dementia is irreversible. Clinical
diagnosis: 98 with dementia and 62 without
dementia
SPECT FTD pattern (bilateral frontal or
frontotemporal area of hypoperfusion) = abnormal
scans; ‘other patterns’ = normal scans
Information from Table 4 (p762) and table 3 (p761)
5 FTD participants: 2 had compatible SPECT
pattern; 2 had MID pattern; 1 had AD pattern
2 abnormal scans (TP = 2); 3 normal scans (FN =
3)
36 AD participants: 23 had compatible SPECT
pattern; 1 had FTD pattern; 10 had MID pattern; 2
had normal pattern
1 abnormal scan (FP = 1); 35 normal scan (TN =
35)
33 MID (VaD) participants: 25 had compatible
SPECT pattern; 2 had FTD pattern; 5 AD pattern; 1
abnormal but unclassified
2 abnormal scan (FP = 2); 31 normal scan (TN =
31)
24 ‘unclassifiable dementia’: 1 had compatible
SPECT pattern; 5 FTD patterns; 1 had AD pattern;
11 had VaD pattern; 6 had normal pattern
5 abnormal scan (FP = 5); 19 normal scan (TN =
19)
62 patients without dementia: all patients had
normal SPECT scan (Table 3, p761)
0 abnormal scan (FP = 0); 62 normal scan (TN =
62)
1) SPECT FTD pattern indicative of FTD (n = 160)
5 D+; 155 D- 
TP = 2; FP = 8; FN = 3; TN = 147
Sensitivity = 40%; Specificity = 95% (calculated in
Revman5)
2) FTD vs AD (n = 41)
TP = 2; FP = 1; FN = 3; TN = 35
Sensitivity = 40%; Specificity = 97% (calculated in
RevMan)
3) FTD vs VaD (n = 38)
TP = 2; FP = 2; FN = 3; TN = 31
Sensitivity = 40%; Specificity = 94% (calculated in
RevMan)
Was there an appropriate interval between index test and reference
standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
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Lipton 2004
Patient Selection
A. Risk of Bias
Patient Sampling
Retrospective design: data used from a longitudinal study;
the cases with neuropathologically diagnosed FTLD and
definite AD in the database were collected for 27
participants
Inclusion criteria: all cases with neuropathologically
diagnosed FTLD and definite AD in the database were
collected. Definite AD participants defined as having both
pathologically confirmed definite AD and a history of at
least one 99mTc-HMPAO SPECT scan during clinical
course
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
In total, 27 participants were included. 23/27
participants had SPECT scan data: 6/10 FTLD
and 17 AD dementia. Participants with
pathologically confirmed diagnosis were
included
Country: USA
No further information
Are there concerns that the included patients and setting do not match the
review question? Unclear
Index Test
Index tests
Xenon or 99mTc-HMPAO SPECT
The degree of lateralisation was semiquantitated by the degree of abnormality: reduced regional
cerebral blood flow (rCBF) on SPECT, noted in the radiologist’s report (0 = no abnormality, 1 = mild or
unspecified, 2 = moderate, and 3 = severe abnormality). Ratings were made for frontal, temporal,
parietal, and occipital lobes on the right and left. Lateralisation for each lobe individually was defined
by greater abnormality on either the right or left. A difference of at least 1 point between left and right
for a given lobe was considered as lateralisation for that lobe. A global rating of lateralisation was
made based on the predominance of left or right lateralisation for one or more lobes
Threshold: not prespecified; SPECT scans were interpreted with knowledge of the clinical diagnosis.
Two different types of SPECT are used
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTLD (differential diagnosis of FTLD
vs AD dementia)
Reference standard: neuropathological diagnoses for
FTLD. The diagnosis of definite AD pathologically
confirmed and a history of at least one 99mTc-HMPAO
SPECT scan during clinical course
Not reported whether the pathological diagnosis was
made without knowledge of SPECT scan, although it is
likely to be independent
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
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B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Interval between SPECT and pathological
diagnosis not reported. However, timing is not
applicable as cross-sectional assessment
Information from Table 1 (p325)
SPECT performed on 6/10 FTLD and 17 AD
participants: all 6 FTLD had ‘abnormal’ SPECT
scan (‘any lateralisation); 10 AD had ‘abnormal’
and 7 ‘normal’ (‘no lateralisation’) SPECT scan
Information from Table 2 (p325)
SPECT: sensitivity = 100%; specificity = 41%;
PPV = 38%; NPV = 100%
FTLD vs AD (any lateralisation on SPECT scan)
(N = 23)
N = 23; disease positive = 6; disease negative =
17
TP = 6; FP = 10; FN = 0; TN = 7 (calculated in
RevMan)
Note: SPECT was not performed on 4
participants with FTD
Was there an appropriate interval between index test and reference
standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? High risk
Notes
Notes  
McNeill 2007
Patient Selection
A. Risk of Bias
Patient Sampling
Retrospective design. Forty-three FTD and 31 AD
patients had been referred between 1985 and
1998 to the Greater Manchester Neurosciences
Center, Salford, UK. Their diagnoses were
pathologically confirmed in Shi Shi 2005 This study
is part of a larger research programme. No further
details
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
Fifty six participants: 25 FTD and 31 AD participants
with pathologically confirmed diagnoses were
included. The clinical records of both FTD and AD
groups were scrutinised. These patients had been
assessed longitudinally using detailed neurological
and neuropsychological evaluation (Neary 1986). The
overall clinical diagnosis had been based on a consensus
between the neurologist and neuropsychologist in a
multidisciplinary setting. This presumptive clinical
diagnosis was before SPECT scanning was recorded.
Patients had been followed up every 6 months until their
death
Gender: 18 F, 38 M (FTD: 7 F; 18 M; AD: 11 F, 20 M)
Age (mean±SD years): FTD: 58.0 ± 10; AD: 61 ± 7
MMSE (mean±SD): FTD: 20 ± 7; AD: 16 ± 6
Duration of disease (mean±SD years): FTD: 4 ± 4; AD: 4 ±
2
Education: not reported
Sources of referral: not reported
Sources of recruitment: tertiary care centre, UK
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
Index tests
99mTc-HMPAO SPECT
Obtained at initial evaluation. SPECT scans, performed within 1 month of the first clinical assessment,
were included in the study
The scans were rated:
0 for normal CBF
1 for abnormal CBF
This rating was performed regionally for frontal, parietal, temporal and occipital regions on the left and
right. Asymmetry was rated as either absent or present (0 and 1, respectively). Blood flow was
assessed using a coloured magenta heat scale. Areas were considered abnormal if they were below
the halfway point of this scale on more than two sections. Finally, a diagnosis was made using a
choice of FTD, AD or 'non-specific'
Threshold: prespecified; visual interpretation of the SPECT images by a consultant in nuclear
medicine, experienced in the interpretation of SPECT images of patients with dementia. They were
reported blind to all clinical and pathological data. However, a single-headed camera was used with no
extended acquisition. Image analysis was not performed. This is against the EANM guidelines and
would represent an obsolete clinical service
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTD (differential diagnosis of FTD vs
AD dementia)
Reference standard: pathological diagnosis (Shi
2005). The diagnosis for AD was made by
Consortium to Establish a Registry for AD criteria
for the neuropathological diagnosis (Mirra 1991)
Is the reference standards likely to correctly classify the target
condition? Yes
Were the reference standard results interpreted without knowledge
of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? Low risk
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B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration until death: mean 4 ± 4 years for FTD;
mean 4 ± 2 years for FTD
Information from Table 2 (page 351):
FTD vs AD analysis (N = 56) (frontal region)
FTD = 25 (disease positive); AD = 31 (disease
negative)
SPECT in FTD participants: 20 (73%) FTD
abnormal (TP = 20); 5 (20%) SPECT normal
(FN = 5)
SPECT in AD participants: 12 (39%) FTD
abnormal (FP = 12); 19 (61%) AD normal (TN =
19)
Sensitivity = 80%; Specificity = 61% (calculated
in Revman5)
FTD vs AD analysis (N = 56) (parietal region)
FTD = 25 (disease positive); AD = 31 (disease
negative)
SPECT in FTD participants: 7 (28%) FTD
abnormal (TP = 7); 18 (72%) SPECT normal
(FN = 18)
SPECT in AD participants: 28 (90%) FTD
abnormal (FP = 28); 3 (10%) AD normal (TN =
3)
Sensitivity = 28%; Specificity = 10% (calculated
in Revman5)
FTD vs AD analysis (N = 56) (temporal region)
FTD = 25 (disease positive); AD = 31 (disease
negative)
SPECT in FTD participants: 15 (60%) FTD
abnormal (TP = 15); 10 (40%) SPECT normal
(FN = 10)
SPECT in AD participants: 27 (87%) FTD
abnormal (FP = 27); 4 (13%) AD normal (TN =
4)
Sensitivity = 60%; Specificity = 13% (calculated
in Revman5)
FTD vs AD analysis (N = 56) (occipital region)
FTD = 25 (disease positive); AD = 31 (disease
negative)
SPECT in FTD participants: 1 (4%) FTD
abnormal (TP = 1); 24 (96%) SPECT normal
(FN = 24)
SPECT in AD participants: 6 (19%) FTD
abnormal (FP = 11); 25 (81%) AD normal (TN =
25)
Sensitivity = 4%; Specificity = 69% (calculated in
Revman5)
Note: all participants with the pathologically
confirmed diagnosis were included in the
analysis
Was there an appropriate interval between index test and reference
standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
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Notes
Notes  
Nagao 2004
Patient Selection
A. Risk of Bias
Patient Sampling
Retrospective study: 21 consecutive
patients with a diagnosis of FTLD were
selected from the data file of the
outpatient clinic between October 1998
and March 2002 (Hokoishi 2001) and 21 patients
with probable AD were randomly sampled from
the same data file. They were matched for sex,
age, duration of dementia and severity of
dementia as estimated with the CDR. Eleven
healthy controls with normal cognitive findings
were recruited from the community
We only included data on performance of the
index test to discriminate between patients with
FTLD and AD dementia
Exclusion criteria: i) the clinical features
described as excluding FTLD by Neary 1998
criteria; ii) an advanced stage of FTLD, with
severe deficits or behavioural disorders that
could have made assessment difficult; iii)
patients with magnetic resonance imaging (MR)
imaging evidence of focal brain lesions and MR
angiographic evidence of occlusive lesions in the
cervical and intracranial arteries were also
excluded
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
42 participants: 21 FTLD and 21 AD. Primary
degenerative dementia patients who satisfied
the DSM-III criteria for dementia were recruited
for this study. FTLD and AD were diagnosed
clinically using the Neary 1998 and McKhann
1984 criteria, respectively.
Gender: FTLD: 14 F and 7 M; AD: 13 F and 8
M
Age (mean±SD years): FTLD: 65.5 ± 6.2; AD:
69.6 ± 6.9
Clinical Dementia Rating (CDR): FTLD: 8 with
a CDR of 0.5 and 13 with a CDR of 1.0; AD: 7
with a CDR of 0.5 and 14 with a CDR of 1.0
MMSE: (mean±SD) FTLD: 23.2 ± 5.4; AD:
21.6 ± 4.6
Sources of referrals: not reported
Sources of recruitment: Higher Brain Function
Clinic for Outpatients of the University Hospital
of Ehime, Matsuyama, Japan
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
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Index tests
99mTc-HMPAO SPECT
740 MBq dose was used. The SPECT images were delineated images using a 35% and a 50%
cut-off of the maximal voxel radioactivity and measured the number of voxels included in the
contours of two different cutoffs. The fractal dimension (FD) was calculated by relating the
logarithms of the cut-offs and the numbers of voxels and it was defined as the heterogeneity of
cerebral perfusion (Chung 2000; Nagao 2002). The SPET images were divided into two sets, anterior
and posterior
Thresholds: not prespecified
anterior FD > 1.46 indicates a clinical diagnosis of FTLD (SPECT positive)
anterior FD to posterior FD > 1.6 indicates a clinical diagnosis of FTLD (SPECT positive)
Not reported whether the results of the index test were interpreted without the knowledge of a clinical
diagnosis
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTLD (differential
diagnosis of FTLD vs AD dementia)
Reference standard: Neary 1998.
The clinical diagnosis of AD was
established by the NINCDS-
ADRDA criteria (McKhann 1984). The
reference standard results were interpreted
without knowledge of the results of the
index test (index test was applied after the
clinical diagnoses were made)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Interval between SPECT and clinical
assessment not reported. However, timing is
not applicable as cross-sectional. A delay is
unlikely to introduce bias as the condition of
dementia is irreversible
FTLD vs AD
1) SPECT result: anterior FD > 1.46
21 FTLD participants: 11 SPECT positive; 10
SPECT negative
21 AD participants: 3 SPECT positive; 18
SPECT negative
TP = 11; FN = 10; FP = 3; TN = 18
Sensitivity = 52%; Specificity = 86%
(calculated in Revman5)
2) SPECT result: anterior FD to posterior FD
> 1.6
21 FTLD participants: 11 SPECT positive; 10
SPECT negative
21 AD participants: 0 SPECT positive; 21
SPECT negative
TP = 11; FN = 10; FP = 0; TN = 21
Sensitivity = 52%; Specificity = 100%
(calculated in Revman5)
Was there an appropriate interval between index test and reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators were contacted; they provided requested data tor the 2 x 2 table
to be completed; email from Dr Nagao on 02/2/13
 
Pickut 1997
Patient Selection
A. Risk of Bias
Patient Sampling
Twenty-one patients clinically diagnosed
with FLD were selected from the records of
a Memory Clinic. Age- and severity-
matched FLD (n = 21) and (S)DAT (n = 19)
groups were considered. No further
information on sampling
Exclusion criteria: patients with concurrent
pathology (vascular dementia, atrophy,
tumours, focal or more than age-associated
atrophy) were excluded
Was a consecutive or random sample of patients enrolled? No
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
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B. Concerns regarding applicability
Patient characteristics and setting
40 participants: 21 FLD and 19 (S)ADT
Age (mean±SD years): 70 ± 9 years in both
groups
MMSE (mean±SD) 15.4 ± 4.9 in the FLD
group; mean 14.8 ± 5.3 in the (S)DAT group
Sources of recruitment: records of memory
clinic. Country: Belgium
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
99mTc-HMPAO SPECT
Threshold: images were assessed qualitatively by visual interpretation on shades of colour in cortical
regions. Brain SPECT perfusion deficits were scored by visual qualitative analysis with respect to
location: frontal, parietal, temporal and occipital; lateralisation: left and or right; and severity score: 0 =
normal (no perfusion deficit); 1 = slight (13% to 30%); 2 = moderate (30% to 50%); 3 = severe (> 50%,
including breaching of the cortex). The probability of predicting (S)DAT based on the SPECT scan is
calculated with the formula (p932), using the severity score of bifrontal hypoperfusion: value ˂ 0.5 was
predictive for FLD; value > 0.5 was predictive for (S)DAT
Threshold: not prespecified
The physicians were unaware of the type and severity of cognitive impairment of the patient studied
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FLD (differentiating FLD vs
senile dementia of Alzheimer's type)
Reference standard: not specified
The diagnosis of probable (S)DAT was based on
the NINCDS-ADRDA criteria. The patients also
fulfilled the DSM IV-criteria
The clinical diagnoses were established before
participants underwent SPECT scans
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have
introduced bias? High risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Interval between SPECT and clinical
assessment not reported. However, timing is
not applicable as cross-sectional. A delay is
unlikely to introduce bias as the condition of
dementia is irreversible
FLD vs (S)DAT
N = 40: 21 FLD (D+): 81% correctly
classified: 17/21: TP = 17; FN = 4; 18
(S)DTA (D-): 74% correctly classified: 14/19:
TN = 14; FP = 5
Sensitivity = 81%; Specificity = 74%
(calculated in RevMan5)
Was there an appropriate interval between index test and reference standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Read 1995
Patient Selection
A. Risk of Bias
Patient Sampling
Twenty seven participants were retrospectively
recruited. They were consecutive dementia
patients, clinically evaluated at a Univeresity
dementia clinic. and were unselected
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
27 patients undergoing full clinical evaluation, including
SPECT, were identified with diagnostic
neuropathological studies by a chart review. Clinical
diagnosis at baseline: 8 FTD; 7 probable AD; 4 possible
AD; 1 AD-LBD variant; 1 AD-vascular; 6 other (2 JCD; 2
MID; 1 MID-AD; 1 hydrocephalus)
Pathologically confirmed diagnosis at follow up: 7 FTLD
(n = 4 FTD & 3 Pick’s disease) and 13 AD. Demographic
data reported for those 20 participants
Gender: 11 M; 9 F
Age: range 42 to 69 years
Sources of recruitment: University-based speciality
dementia clinic. Country: USA
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
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Index tests
99mTc-HMPAO SPECT
Threshold: prespecified; four patterns emerged, each corresponding to a distinct pathological entry. All
SPECT scans were interpreted visually by a nuclear medicine physician blinded to clinical diagnosis.
SPECT predicted pathology in 93%
The SPECT methodology section is unclear in this paper. Two types of camera are mentioned, one of
which would not meet the criteria of the EANM and SNM guidelines. However, the other camera is a
dedicated brain system. The authors do not state the proportion of patients imaged on each system. In
addition standard clinical practice was not followed with regards to rest times following injection of the
radiotracer
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTLD (differential
diagnosis of FTD versus AD dementia)
Reference standard: pathology (brain
biopsy or post-mortem brain pathology)
In all of the patients clinical diagnosis was
made before using SPECT
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results
of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
There was an appropriate interval between index test
and referense standard (pathohystology or brain
biopsy).
1) SPECT FTD type pattern indicative of FTD
confirmed pathologically (n = 27) (Table 1, p1244)
Participants (N = 27): 7/27 had ‘SPECT FTD type
pattern’: ‘positive test’; 20/27 ‘SPECT other type
pattern’: ‘negative test’
All 7 participants with SPECT ‘positive test’ were
pathologically diagnosed with FTLD (FTD) (1 with
biopsy and 6 with histopathology). No participant
with SPECT ‘negative’ test was diagnosed with
FTLD (FTD)
TP = 7; FP = 0; FN = 0; TN = 20; Sensitivity = 100%;
Specificity = 100%
2) FTLD vs AD (n = 20) (Table 1, p1244)
TP = 7; FP = 0; FN = 0; TN = 13; Sensitivity = 100%;
Specificity = 100%
All participants pathologically diagnosed with FTD
and AD were included in analyses
Was there an appropriate interval between index test and reference
standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes  
Rollin-Sillaire 2012
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Patient Selection
A. Risk of Bias
Patient Sampling
Retrospective study of 48 consecutive patients
with a degenerative or vascular dementia who
were referred to a memory clinic between 1989
and 2008
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics and setting
48 participants patients: 25 with a clinical
diagnosis of AD; 19 with a clinical diagnosis of
FTLD/PSP/CBD; 5 with 'other' clinical diagnoses.
The caseload database (1989 to 2008) at the
Lille/Bailleul memory clinic was reviewed to
identify all patients who had: i) a clinical diagnosis
of dementia disorder, ii) SPECT imaging data,
and iii) a definite diagnosis determined by
neuropathological or genetic evidence. All
medical records were reviewed by two
neurologists blinded to the definite diagnosis and
SPECT images. These clinical diagnoses were
made at time of SPECT acquisition and just
before death, according to the international
diagnostic criteria (Cairns 2007; Ball 1997).
Age at first symptom (median; mean±SD years): total
sample: 62.8; 61.6 ± 9.6; FTLD/PSP/CBD: 58.9; 57.4 ±
10.3; AD: 62.9; 62.4 ± 7.8
Age at SPECT (median; mean±SD years): total sample:
68.5; 67.3 ± 8.9; FTLD/PSP/CBD: 64.9; 62.1 ± 10.5; AD:
69.2; 65.5 ± 6.2
Time between first symptom and first visit (median;
mean±SD years): total sample: 3.3; 4.4 ± 3.6;
FTLD/PSP/CBD: 2.8; 3.6 ± 3.1; AD: 5.7; 5.5 ± 5.6
Time between first symptoms and SPECT (median;
mean±SD years): total sample: 4.7; 5.8±3.8;
FTLD/PSP/CBD: 3.7; 4.7±3.2; AD: 5.4; 6.9±3.8 Time
between first visit and SPECT (median; mean±SD
years): total sample: 0.3; 1.4±1.9; FTLD/PSP/CBD: 0.6;
1.1±1.3; AD: 0.2; 1.4±2.1
MMSE at first visit (median; mean±SD): total sample:
total sample: 20; 19.5±6.7; FTLD/PSP/CBD: 24;
23.8±3.4; AD: 15; 14.6±8.1
MMSE at the time of SPECT (median; mean±SD): total
sample: 19; 17.6±7.6; FTLD/PSP/CBD: 20.5;
231.2±34.5; AD: 18; 16.9±7.2
Age at death (median; mean±SD years): total sample:
73.5; 72.3±9.5; FTLD/PSP/CBD: 67.4; 66.1±10.9; AD:
75; 75.1±6.8
Duration of (median; mean±SD years): total sample: 9.6;
10.8±4.7; FTLD/PSP/CBD: 8.5; 8.6±3.2; AD: 12.6;
12.7±4.8
Sources of recruitment: Lille-Bailleul Memory Clinic,
University of Lille Nord de France
Are there concerns that the included patients and setting do not
match the review question? Low concern
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Index Test
Index tests
99mTc-HMPAO SPECT
All SPECT images were acquired between 1990 and 2006. SPECT imaging data were
normalised and represented by fixation values according to a coloured scale for immediate
ranking: a value of less than 80% was considered to be significant (Steinling 1988). This cut-
off was inially determined to obtain a specificity of 100% and a specificity of 60% for AD
diagnosis (Steinling 1989)
Threshold: prespecified; visual interpretation
Index test was interpreted without the knowledge of reference standard
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target conditions: FTLD (differential
diagnosis of FTLD vs 1) AD and 2) non-
FTLD)
Reference standards: pathological diagnosis
for FTLD was established by the Cairns
2007 criteria. The pathological diagnosis for
AD was made by the Ball 1997 criteria
The reference standard results were
interpreted without knowledge of the index
test
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
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A. Risk of Bias
Flow and timing
Duration of follow up: participants were followed
until death
At baseline: N = 48 participants with a clinical
diagnosis of dementia disorder (9 SPECT with FTLD
pattern; 1 SPECT with PPA; 38 SPECT with ‘other’
patterns) (p836)
At follow up: neuropathology was performed in 47
patients and genetic mutation in one patient (data
provided by the author)
1) SPECT FTD pattern indicative of FTD (n = 48)
SPECT ‘FTD type pattern’ = 10 ‘positive tests’: 9
FTLD (disease positive) and 1 non-FTLD (disease
negative)
SPECT ‘other or normal type pattern’ = 38 ‘negative
tests’: 3 FTLD (disease positive) and 35 non FTLD
(disease negative)
TP = 9; FP = 1; FN = 3; TN = 35; Sensitivity = 75%;
Specificity = 97% (calculated in Revman5)
2) FTD vs AD (N = 35)
12 patients with FTLD pathological diagnosis
(including 2 Pick's dementia and 1 PGRN mutation)
at follow up: 9 with FTLD SPECT pattern and 1 with
PPA pattern (positive tests) TP = 9; 3 with 'other'
SPECT patterns (2 with DLB pattern; 1 with non-
specific hypoperfusion) (negative test) FN = 3
23 patients with AD pathological diagnosis at follow
up: 0 with FTLD SPECT pattern (positive tests) FP =
0; 23 with 'other' SPECT patterns (negative test) TN
= 23
Sensitivity = 75%; Specificity = 100% (calculated in
Revman5)
Loss to follow up: none
Was there an appropriate interval between index test and reference
standard? Yes
Were all patients included in the analysis? Yes
Could the patient flow have introduced bias? Low risk
Notes
Notes The trial investigators were contacted; they provided some requested data tor the 2 x 2
table to be completed; email from Dr Rollin-Silliare on 21/2/13
 
Talbot 1998
Patient Selection
A. Risk of Bias
Patient Sampling
A sample of 363 patients who were
consecutively referred to the cerebral function
unit at Manchester Royal Infirmary for
diagnostic assessment of dementia
Exclusion criteria: not reported
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics and setting
363 participants with suspected dementia underwent
neuropsychological evaluation, neurological examination,
CT, and 99mTc-HMPAO SPECT at initial presentation.
Patients were reviewed prospectively for a median three
(range 1–6) years with six monthly neuropsychological and
neurological evaluation, and classified on the basis of
established clinical criteria into a number of disease
groups. Age and gender were reported in the five largest
groups (N = 314): AD (132), vascular dementia (78), Lewy
body disease (24), frontotemporal dementia (58) and
progressive aphasia (22)
Gender: FTD: 26 F; 32 M; AD: 80 F, 52 M; VaD: 37 F; 41
M; LBD: 10 F; 14 M; progressive aphasia: 15 F; 7 M
Age (mean±SD years): FTD: 58.9 ± 1.1; AD: 58.9 ± 1.1;
VaD: 63.6 ± 8.1; LBD: 67.6 ± 4.8; progressive aphasia
(PA): 64.9 ± 6.8
MMSE (mean±SD): not reported
Education (mean±SD years): not reported
Sources of referral: not reported
Sources of recruitment: Hospital Cerebral Functional Unit,
Manchester, UK
Are there concerns that the included patients and setting do not
match the review question? Low concern
Index Test
Index tests
99mTc-HMPAO SPECT
The index test was performed on all 363 participants at baseline (within one month of initial
presentation). The 99mTc-HMPAO SPECT images were reported by a consultant in nuclear medicine
experienced in the interpretation of CBF images. Images were viewed on a monitor with standardised
display settings and reported blind to clinical and CT findings
Threshold: not prespecified: visual interpretation, using magenta scale: bilateral anterior CBF
abnormality or bilateral anterior plus unilateral posterior CBF abnormality (SPECT indicative of FTLD)
The threshold above provides support for frontotemporal dementia (p311). It was not reported whether
the index test results were interpreted without knowledge of the results of the reference standard. A
single-headed camera was used with no extended acquisition. Image analysis was not performed.
This is against the EANM guidelines and would represent an obsolete clinical service
Reference Standard
A. Risk of Bias
Target condition and reference standard(s)
Target condition: FTD: differential diagnosis of
FTD vs i) AD dementia and ii) VaD
Reference standard: the Brun 1994 criteria; in
four patients the clinical diagnosis was confirmed
pathologically Mann 1993). The clinical
diagnosis for AD and vascular dementia
were established by the NINCDS-
ADRDA (McKhann 1984) and Román 1993
criteria, respectively. Pathological confirmation of
AD was established in eight patients (Mann 1993)
Not reported whether the reference standard
results were interpreted without knowledge of the
results of the index test
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have
introduced bias? Unclear risk
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B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Duration of follow up: median 3 years (range 1 to
6 years)
Index test: SPECT 'bilateral anterior' or 'bilateral
anterior plus unilateral posterior' CBF
abnormality
At baseline: 363 participants with suspected
dementia
At follow up: 132 AD; 58 FTD; 78 VD; 24 LBD; 22
progressive aphasia; 49 ‘other’ (according to the
clinical diagnosis)
Information from Table 2 (p307)
1) SPECT FTD pattern indicative of FTD 
SPECT pattern: bilateral anterior brain
hypoperfusion
Participants: 132 AD; 58 FTD; 78 VD; 24 LBD; 22
progressive aphasia (n = 314)
TP = 21; FP = 21; FN = 37; TN = 235
Sensitivity = 36%; specificity = 92% (calculated in
RevMan5)
2) FTLD vs AD
SPECT pattern: bilateral anterior and bilateral
anterior & unilateral posterior brain hypoperfusion
Participants: FTLD (FTD & PA) = 80; AD = 132
(N = 212)
TP = 37; FP = 5; FN = 43; TN = 127
Sensitivity = 46%; specificity = 96% (calculated in
RevMan5)
2) FTLD vs VD
SPECT pattern: bilateral anterior and bilateral
anterior & unilateral posterior brain hypoperfusion
Participants: FTLD (FTD & PA) = 80; VaD = 78
(N = 158)
TP = 37; FP = 21; FN = 43; TN = 57
Sensitivity = 46%; specificity = 73% (calculated in
RevMan5)
Loss to follow up: 49 participants with ‘other’
clinical diagnosis not included because the
relevant information for those patients are not
reported
Was there an appropriate interval between index test and reference
standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Valotassiou 2012
Patient Selection
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A. Risk of Bias
Patient Sampling
112 consecutive patients from the outpatient
hospital memory clinic
Exclusion criteria: pregnant women, patients
with a history of psychiatric disorders and
patients with signs or findings of other
neurological disorders and patients with the
presence of vascular or structural brain
lesions
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics and setting
112 participants: 73 FTLD (bvFTLD = 20;
PNFA = 11; SD = 21; CBD/PSP = 21) and 39
AD
Gender: FTLD: 52 F; 21 M; AD: 29 F 10 M
Age (mean±SD years): FTLD: 65± 9; AD: 71
± 8
MMSE (mean±SD): FTLD: 16 ± 9; AD: 19 ± 5
Education: (mean±SD years)FTLD: 10.7± 4.7;
AD: 9.3± 4.7
Years of disease (mean±SD): FTLD: 3± 2;
AD: 4± 2
Sources of referral: not reported
Sources of recruitment: outpatient hospital
memory clinic of the General Hospital,
Larrisa, Greece
Are there concerns that the included patients and setting do not match the
review question? Low concern
Index Test
Index tests
99mTc-HMPAO SPECT
740 MBq dose was administered
NeuroGram software on the restricted data for the semiquantitative evaluation of brain perfusion in
specific Broadmann areas (BA) was used. This is the method of statistical analysis for automated
diagnosis of brain perfusion SPECT images. A predefined anatomical and BA template for the
semiquantitative analysis was used in order to investigate brain perfusion.
Threshold: not prespecified; the optimal sensitivity and specificity of various cut-off perfusion values
were determined from ROC curves
Computer program used for the interpretation of the results of the index test
Reference Standard
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A. Risk of Bias
Target condition and reference standard(s)
Target condition: i) bvFTLD or ii) PNFA or
iii) SD vs AD dementia (differential
diagnosis)
Reference standard: Neary 1998
criteria. The clinical diagnosis of
AD dementia was established by
the NINCDS-ADRDA (McKhann 1984)
The clinical diagnosis of dementia was
made before performing SPECT scans
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the
results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced
bias? Low risk
B. Concerns regarding applicability
Are there concerns that the target condition as defined by the reference standard does not match the question? Lowconcern
Flow and Timing
A. Risk of Bias
Flow and timing
Interval between SPECT and clinical
assessment not reported. However, timing is
not applicable as cross-sectional. A delay is
unlikely to introduce bias as the condition of
dementia is irreversible
Participants: 73 FTLD (bvFTLD = 20; PNFA =
11; SD = 21; CBD/PSP = 21) and 39 AD
Information from Table 4 (p1271)
1) bvFTLD vs AD (n = 59)
bvFTLD = 20 (disease positive); AD = 39
(disease negative); sensitivity = 75%;
specificity = 79%
TP = 15; FP = 8; FN = 5; TN = 31 (calculated
in Revman5)
2) PNFA vs AD (n = 50)
PNFA = 11 (disease positive); AD = 39
(disease negative); sensitivity = 76.9%;
specificity = 63.4%
TP = 8; FP = 14; FN = 3; TN = 25 (calculated
in Revman5)
3) SD vs AD (n = 50)
SD = 21 (disease positive); AD = 39 (disease
negative); sensitivity = 81%; specificity = 51%
TP = 17; FP = 19; FN = 4; TN = 20
(calculated in Revman5)
We did not include 21 CBD/PSP patients in
the analyses; they are not the patients with
the target condition considered in the review
Was there an appropriate interval between index test and reference
standard? Yes
Were all patients included in the analysis? No
Could the patient flow have introduced bias? Unclear risk
Notes
Notes  
Footnotes
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AD=Alzheimer's disease dementia; FTD=frontotemporal dementia; VaD=vascular dementia; LBD=Lewy body dementia;
SPECT=single-photon emission computerised tomography; MRI=magnetic resonance imaging; CSF=cerebrospinal fluid;
CAD=clinically ambiguous dementia; DSM=Diagnostic and Statistical Manual of Mental Disorders; MMSE=The Mini Mental
State Examination; NINCDS-ADRDA=National Institute of Neurological and Communicative Disorders and Stroke and the
Alzheimer's Disease and Related Disorders Association; ±SD= ±standard deviation; 99mTc-HMPAO=Technetium
exametazime hexamethylpropyleneamine oxime; RevMan5; Review Manager 5; NINDS-AIREN=National Institute of
Neurological and Communicative Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement
en Neurosciences; TP: true positive; FP: false positive; FN: false negative; TN: true negative; 3D Tc-99m ECD=three-
dimensional spaceTechnetium exametazime ethyl cysteinate diethylester; PLS=partial least square; SPEC=specific causes
of dementia; MID: multi-infarct dementia; rCBF=regional cerebral blood flow; EANM=European Association of Nuclear
Medicine; FTLD=frontotemporal lobar degeneration; PPV=positive predictive value; NPV=negative predictive value; CDR=;
FD=fractal dimension; CDR=clinical dementia rating; (S)DAT=(Senile) demenia of the Alzheimer's type; D+ = disease
positive; D+ = disease negative; SNM: Society of Nuclear Medicine; bvFTLD=behavioural variant frontotemporal
degeneration; PNFA=progressive nonfluent aphasia; CBD/PSP=corticobasal degeneration/ progressive supranuclear palsy;
PPA=primary progressive aphasia; CT=computerised tomography; BA: Brodmann area; ROC=receiver operating
characteristic; SD=semantic dementia
Characteristics of excluded studies 
Barnes 2000
Reason for exclusion Not having data for constructing a 2 x 2 table. Target condition: not differential
diagnosis of FTD vs other forms of dementia. The focus of the study was to investigate
whether SPM is an effective decision and whether it impacts on the confidence of
image reporting
 
Barquero 1996
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: PPA variant FTD;
participants with other forms of dementia not included
 
Boeve 2012
Reason for exclusion Not having data for constructing a 2 x 2 table for FTD. Genetic analysis performed
 
Bonte 1994
Reason for exclusion Not having data for constructing a 2 x 2 table for FTD. Target condition: Alzheimer's
diasease dementia participants: only 4/30 patients had frontal dementia pathological
diagnosis
 
Bonte 2004
Reason for exclusion Not having data for constructing a 2 x 2 table. Target condition: Alzheimer's disease
dementia not FTD. Index test: AD SPECT pattern observed
 
Borghesani 2010
Reason for exclusion Insufficient data to complete 2 x 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Borroni 2010
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: bvFTD, SD and PNFA
variant only; participants with other frorms of dementia not included. The focus of the
study was to evaluate the correlation between FTLD-modified Clinical Dementia
Rating (CDR) scale and the degree of frontotemporal hypoperfusion in patients with
FTLD
 
Borroni 2012
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Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: bvFTD and SD variant FTD
only; participants with other forms of dementia not included. The focus of the study
was to evaluate whether SPECT scan may be useful to predict prognosis of long-term
survival in FTLD patients
 
Buchpiguel 1996
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: at follow up only 1
participant with FTD
 
Didic 1998
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: FTD patients only;
participants with other types of dementia not included. Target condition: not differential
diagnosis of FTD vs other types of dementia
 
Frisoni 1992
Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: threshold not used.
Participants: 5 FTD and 5 AD. The AD participants were 'atypical': one participant had
vivid hallucinations and one had delusions
 
Frisoni 1995
Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: threshold not used. Target
condition not differential diagnosis of FTD vs other types of dementia. The focus of the
study was to assess the neuropsychological SPECT imaging feature in DFT and AD
participants
 
Grace 2001
Reason for exclusion Not having data for constructing a 2 x 2 table. Target condition: not differential
diagnosis of FTD vs other types of dementia. The focus of the study was to evaluate
the relationship of behavioural changes to other diagnostic information regarding
dementia (SPECT, neuropsychological performance, depressive symptomatology)
 
Hannequin 2001
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: PPA variant FTD patients
only. Participants with other forms of dementia not included. Target condition: not
differential diagnosis of FTD vs other types of dementia
 
Hogh 2004
Reason for exclusion Not having data for constructing a 2 x 2 table. Target condition: not FTD. The focus of
the studies was not identifying those participants with a questionable dementia at
baseline who would develop FTD at follow up
 
Honda 2002
Reason for exclusion Not having data for constructing a 2 x 2 table. The focus of the study was to evaluate
interobserver variation in diagnosis of dementia by brain perfusion SPECT
 
Joseph 2006
Reason for exclusion Not having data for constructing a 2 x 2 table. Only one patient out of five with FTLD
pathological diagnosis had a SPECT scan at baseline
 
Julin 1995
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Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: threshold not used. Target
condition: not differential diagnosis of FTD vs AD dementia
 
Kaneko 2004
Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: 99mTc-HMPAO SPECT:
posterior cingulate perfusion was observed only in 13/20 AD patients and in 5/20
SDAT patients. The index test was not performed in the patients with FTD
 
Le Ber 2006
Reason for exclusion Participants: fvFTD patients only; participants with other types of dementia not
included. Target condition: not differential diagnosis of FTD vs other types of dementia
 
Lojkowska 2002
Reason for exclusion Not having data for constructing a 2 x 2 table. Descriptive analysis reported
 
Mendez 2007
Reason for exclusion Insufficient data to complete 2 x 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Miller 1997
Reason for exclusion Not having data for constructing a 2 x 2 table. Aim of the study: to assess the of the
Lund-Manchester research (LMRC) criteria for FTD. The initial research question was
whether any of the items on the LMRC could reliably distinguish between FTD and AD.
A SPECT scan was used as a reference standard not an index test
 
Miller 1999
Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: threshold not used. The
focus of the study was to evaluate SPECT scans against the presence of right or left
frontal or temporal hypoperfusion in participants with FTD
 
Papma 2013
Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: threshold not used. The
focus of the study was to evaluate SPECT scan hypoperfusion patterns in FTD with
and without episodic memory impairment and in early onset of AD dementia
 
Sjogren 2000
Reason for exclusion Insufficient data to complete 2 x 2 tables. Additional data were requested from the trial
investigators but no further information was available at the time this review was
prepared
 
Talbot 1995
Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: threshold not used. This
study evaluated differences in the patterns of rCBF data between groups
 
Valotassiou 2009
Reason for exclusion Not having data for constructing a 2 x 2 table. Index test: threshold not used. The
focus of the study was to evaluate the perfusion of specific BA areas of the brain
cortex in FTD and AD patients, using NeuroGam processing program
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Valotassiou 2011
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: SD variant FTD and AD
(data extractable for SD vs AD)
 
Valotassiou 2012a
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: PNFA variant FTD and AD
 
Valotassiou 2012b
Reason for exclusion Not having data for constructing a 2 x 2 table. Participants: SD and PNFA variant FTD
only
 
Waragai 2008
Reason for exclusion Not having data for constructing a 2x 2 table. Target condition: AD dementia not FTD
 
Footnotes
FTD=frontotemporal dementia; SPM=Statistical Parametric Maps; PPA=primary progressive aphasia; FTD=frontotemporal
dementia; AD=Alzheimer's disease; SPECT=single-photon emission computerised tomography; bvFTD= behavioural variant
frontotemporal degeneration; SD=semantic dementia; PNFA=progressive nonfluent aphasia; CDR=Clinical Dementia Rating
scale; FTLD=frontotemporal lobar degeneration; DFT=dementia of frontal type; ; 99mTc-HMPAO=Technetium exametazime
hexamethylpropyleneamine oxime; SDAT=senile dementia Alzheimer's type; fvFTD=frontal variant frontotemporal dementia;
PNFA= progressive nonfluent aphasia
Characteristics of studies awaiting classification 
Footnotes
Characteristics of ongoing studies 
Footnotes
Summary of results tables
1 Performance of rCBF SPECT for detection of frontotemporal dementia
Is the SPECT FTD pattern indicative of developing FTD over time in populations with suspected dementia? What is the
diagnostic accuracy of rCBF SPECT biomarker for discriminating FTD from non-FTD, and FTD from Alzheimer's disease
dementia and other dementia subtypes?
Population 
Participants with suspected dementia and rCBF SPECT administered at baseline (prospective cohort
design) (n = 3)
Participants with suspected dementia and rCBF SPECT administered at baseline with histopathological
confirmation (retrospective cohort design) (n = 2)
Participants clinically diagnosed with FTD or other dementia subtypes using standard clinical diagnostic
criteria (case-control design) (n = 6)
Setting
Outpatients from University centres or University memory clinics (n = 7)
Outpatients from General Hospital memory clinics (n = 1)
Tertiary referral centre (n = 1)
Multicentre (different French hospitals) (n = 1)
Not reported (n = 1)
Sampling
procedure
Consecutive or random (n = 3)
Not consecutive or random (n = 4)
Not reported (n = 4)
Prior testing Prior to performing rCBF SPECT scans, diagnostic criteria for identifying dementia subtypes were applied instudies that used a case-control study design
Index tests 99mTc-HMPAO SPECT; 99mTc-ECD SPECT; Xenon SPECT
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Threshold
prespecified at
baseline
Yes (n = 6)
No (n = 3)
Unclear (n = 2)
Threshold Included studies used a range of thresholds
SPECT scan
interpretation
Combined visual and semiquantitative interpretation (n = 6)
Visual interpretation only (n = 5)
rCBF
hypoperfusion
region
Authors used brain regions that were expected to be affected by FTD and so frontal and/or temporal lobes
were involved in all studies. Two studies also included parietal and occipital lobes in their evaluations. One
study used a range of Broadmann areas (BAs)
Target
condition
Frontotemporal dementia (FTD): ante-mortem clinical diagnosis of FTD (n = 7) or neuropathological
diagnosis of FTD (n = 4)
Reference
standard
For ante-mortem clinical diagnosis: Neary 1998 criteria (n = 4); Brun 1994 criteria (n = 1); not specified (n =
2)
For neuropathological diagnosis: Shi 2005 (n = 1); Cairns 2007 (n = 1); not specified (n = 2)
Diagnostic
criteria for
dementia
subtypes
For AD dementia: NINCDS-ADRDA criteria (n = 6); not specified (n = 1); histopathological criteria (n = 4)
For vascular dementia: NINDS-AIREN criteria (n = 2); histopathological (n = 1)
Included
studies
Eleven studies (n = 1077 participants) assessed rCBF SPECT for differentiating between FTD and AD. Five
of these studies (n = 609) also assessed rCBF SPECT for differentiating between FTD and non-FTD
Reference standard: neuropathological diagnosis. Objective A: rCBF SPECT FTD type pattern (at baseline) indicative of
FTD (at follow up) in participants with suspected FTD at baseline; Objective B: The accuracy of rCBF SPECT pattern in
differentiating FTD from AD
Objective Study N
Confirmed
FTD
Sensitivity
(95% CI)
Specificity
(95% CI)
Quality Comment
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A Read1995 277
100%
(0.59,
1.00)
100%
(0.83,
1.00)
 
Unclear risk of bias
was seen in the
patient selection
QUADAS-2 domain.
The remaining three
domains considered
to be at low risk of
bias. There were no
concerns about
applicability (Read 1995; 
Rollin-Sillaire 2012).
High risk of bias
was seen in patient
selection, index
test, and flow and
timing QUADAS-2
domains. The
reference standard
was strength of the
study. There were
no concerns about
applicability (Lipton 2004)
High risk of bias
was seen in
participant
selection and
index test domain.
The reference
standard was
strength of the
study. There were
no concerns
about applicability
(McNeill 2007)
 
Objective A: These papers used the
gold standard of histopathological
diagnosis; however. the methods
used in participant selection and
image analysis have led to the
introduction of a degree of bias
Objective B: These papers used the
gold standard of histopathological
diagnosis. Although the diagnosis is
robust, case-control design, small
study numbers, different
methodologies with a wide range of
sensitivities and specificities mean
that it is difficult to make
recommendations on the basis of
these results
A
Rollin-
Sillaire
2012
489
75%
(0.43,
0.95)
97%
(0.85.
1.00)
B Read1995 207
100%
(0.59,
1.00)
100%
(0.75,
1.00)
B
Rollin-
Sillaire
2012
359
75%
(0.43,
0.95)
100%
(0.85,
1.00)
B Lipton2004 236
100%
(0.54,
1.00)
 
41%
(0.18,
0.67)
B McNeill2007 5620
80%
(0.59,
0.93)
61 %
(0.42,
0.78)
Investigation 
of
heterogeneity
We were not able to formally assess the effect of potential sources of heterogeneity because meta-
analyses were not performed
Conclusion
Further research on the use of rCBF SPECT for differentiating FTD from other dementias is required. In
particular, protocols should be standardised, study populations well described, threshold for 'abnormal'
scans predefined and clear details given on how scans are analysed
Footnotes
rCBF=regional cerebral blood flow; SPECT=single-photon emission computerised tomography; FTD=frontotemporal
dementia; 99mTc-HMPAO=Technetium exametazime hexamethylpropyleneamine oxime; 99mTc-ECD=Technetium
exametazime ethyl cysteinate diethylester; AD=Alzheimer's disease; NINCDS-ADRDA=National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; NINDS-
AIREN=National Institute of Neurological and Communicative Disorders and Stroke and Association Internationale pour la
Recherche et l'Enseignement en Neurosciences; QUADAS-2=Quality Assessment of Diagnostic Accuracy Studies
Additional tables 
1 Cross classification (2 x 2) table of rCBF SPECT results agisting disease status (based on reference
standard results)
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rCBF SPECT Reference standard
(Lund-Manchester; NINDS;
histopathological criteria)
FTD present
(disease positive)
FTD absent
(disease negative)
'FTD pattern' present
(test positive)
True positive False positive
'FTD pattern' absent
(test negative)
False negative True negative
Footnotes
2 Summary of characteristics of included studies
Author 
year
(country)
Target population  
Study
size
(number
analysed
in
review)
Sampling
procedure
Number of
cases (FTD)
identified by
reference
standard
 
Index
test/camera/interpretation/brain
hypoperfusion
Reference
standard/target
condition
 
Sensitivity
Specificity
Prospective cohort studies
Boutoleau-
Bretonniere
2012
(France)
Neurological Memory Center attendees with
clinically ambiguous dementias
 
69 (19,
29 or 60)
Not
reported
11/60 99mTc-HMPAO
SPECT/multiple camera
visual/frontal ± temporal
Clinical
diagnosis
FTD vs non-
FTD
8/11
0.73
[0.39.0.94]
39/49
0.80
[0.66-0.90]
FTD vs AD 8/11
0.73
[0.39,
0.94]
17/18
0.94
[0.73,
1.00]
FTD vs VD 8/11
0.73
[0.39,
0.94]
6/8
0.75
[0.35,
0.97]
Talbot
1998*
(UK)
Memory clinic attendees with suspected
dementia
 
363
(158,
212 or
314)
Consecutive  
58
(FTD)/363
80 (FTD &
PPA)/363
99mTc-HMPAO
SPECT*/single
camera/visual/bilateral
anterior+ and bilateral
anterior & unilateral posterior++
Clinical
diagnosis
FTD vs non-
FTD
21/58
0.36+
[0.24,0.50]
 
235/256
0.92 +
[0.88, 0.95]
FTD vs AD 37/80
0.46++
[0.35; 0.58]
127/132
0.96++
[0.91; 0.99]
FTD vs VD 37/80
0.46++
[0.35, 0.58]
57/78
0.73++
[0.73, 0.62]
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Launes
1991*
(Finland)
Memory clinic attendees with suspected
dementia
 
160 (41
or 160)
Consecutive  
5/160
99mTc-HMPAO* SPECT/single
camera/visual/frontal bilateral
or frontal-temporal
Clinical
diagnosis
FTD vs non-
FTD
2/5
0.40
[0.05,0.85]
147/155
0.95
[0.90,
0.98]
FTD vs AD 2/5
0.40
[0.05,
0.85]
35/36
0.97
[0.85,
1.00]
FTD vs VD 2/5
0.40
[0.05,
0.58]
31/33
0.94
[0.80,
0.99]
 
Retrospective cohort studies with post-mortem diagnosis
Read
1995**
(USA)
 
AD/FTD/JCD/MID/LBD/hydrocephalus
recruited from a chart review of the
University-based speciality dementia clinic
 
27 (20 or
27)
Not
reported
7/27  
99mTc-HMPAO SPECT/double
camera/visual/bilateral frontal
Pathological
diagnosis
FTD vs non-
FTD
7/7
1.0
[0.59,
1.00]
20/20
1.0
[0.83,
1.00]
FTD vs AD 7/7
1.0
[0.59,
1.00]
13/13
1.0
[0.75,
1.00]
Rollin-
Sillaire
2012
(France)
 
AD/DLB/FTD/VD/FTLD/bvFTD/SD/PPA/PSP/
CBD recruited from the caseload database of
the University memory clinic
 
48 (35 or
48)
Selected
from initially
consecutive
sample
12/48  
99mTc-HMPAO
SPECT/multiple camera
combined visual and semi-
quantitative/frontal
Pathological
diagnosis
FTD vs non-
FTD
9/12
0.75
0.43, 0.95]
35/36
0.97
[0.85,1.00]
FTD vs AD 9/12
0.75
[0.43,
0.95]
23/23
1.0
[0.85,
1.00]
Case-control studies
Horn
2007
(France)
FTD/AD recruited from a number of hospitals  
173
(173)
Not
consecutive
or random
91/173 Tc-99m ECD SPECT/multiple
camera/visual/automatic
classifier for whole brain
Clinical
diagnosis
FTD vs AD
77/91
0.85
[0.76,
0.91]
67/82
0.82
[0.72,
0.89]
Lipton
2004
(USA)
FTD/AD. Sources of recruitment not reported  
27 (23)
Not
consecutive
or random
6/23 Xenon or 99mTc-HMPAO
SPECT/multiple
camera/combined visual and
semiquantitative/global
lateralisation
Pathological
diagnosis
FTD vs AD
6/6
1.00
[0.54,
1.00]
7/17
0.41
[0.18,
0.67]
McNeill
2007*
(UK)
AD /FTD recruited from a tertiary care centre  
56 (56)
Not
consecutive
or random
25/56  
99mTc-HMPAO SPECT*/single
camera/combined visual and
semiquantitative/bifrontal
Pathological
diagnosis
FTD vs AD
20/25
0.80
[0.59,
0.93]
19/31
0.61
[0.42,
0.78]
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Nagao
2003
(Japan)
FTD/AD recruited from the Higher Brain
Function Clinic for outpatients of the
University Hospital + healthy controls (not
included in the analysis)
 
42 (42)
From data
file of
initially
consecutive
sample
21/42 99mTc-HMPAO SPECT
multiple camera
semiquantitative/Bifrontal+++
or bifrontal & posterior++++
Clinical
diagnosis
FTD vs AD
11/21
0.52+++
[0.30; 0.74]
 
18/21
0.86+++
[0.64, 0.97]
FTD vs AD  
11/21
0.52++++
[0.30, 0.74]
21/21
1.0++++
[0.62, 0.82]
 
Pickut
1996
(Belgium)
FTD/AD recruited from a memory clinic  
40 (40)
Not
consecutive
or random
21/40 99mTc-HMPAO SPECT
multiple camera
combined visual and
semiquantitative/frontal and
temporal
Clinical
diagnosis
FTD vs AD
17/21
0.81
[0.58,
0.95]
14/19
0.74
[0.49,
0.91]
Valotassiou
2012
(Greece)
 
FTLD (bvFTD; lvFTD; PNFA; CBD+PSP)/AD
recruited from an outpatient memory clinic of
the General Hospital
21 CBD+PSP participants not included in the
analysis; they are not the patients with the
target condition considered in the review
 
112 (59
or 60 or
50)
Consecutive  
20
(bvFTLD)/59
21 (SD)/60
11
(PNFA)/50
99mTc-HMPAO
SPECT/multiple camera
semiquantitative/brain
Broadmann areas
Clinical
diagnosis
bvFTD vs AD
 
15/20
0.75
[0.51,
0.91]
 
31/39
0.79
0.64, 0.91]
SD vs AD 17/21
0.81
[0.58,
0.95]
20/39
0.51
[0.35,
0.68]
PNFA vs AD 8/11
0.73
[0.39,
0.94]
25/39
0.64
0.47, 0.79]
Footnotes
N = number of participants in the study; n = number of participants included in the analysis in the review; *Study used a
single-headed camera with no extended acquisition and did not use image analysis; **Study used two cameras but details of
total counts can only realistically apply to the brain-dedicated camera; + bilateral anterior brain hypoperfusion; ++ bilateral
anterior & unilateral posterior brain hypoperfusion; +++bifrontal brain hypoperfusion; ++++ bifrontal & posterior brain
hypoperfusion; bvFTD = behavioural variant frontotemporal degeneration; CBD = corticobasal degeneration; FTLD =
frontotemporal degeneration; JCD = Jakob-Creutzfeldt Disease; lvFTD = language variant frontotemporal degeneration; MID
= mixed dementia; PM = post-mortem; PPA = primary progressiva aphasia; PNFA = progressive non-fluent aphasia, PSP =
progressive supranuclear palsy; SD = semantic dementia; SPECT = Single photon emission computed tomography; 99mTc-
HMPAO = 99mTc-hexamethylpropyleneamineoxime
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Data and analyses 
Data tables by test
Test StudiesParticipants
1 FTD versus non-FTD: Single-headed camera rCBF SPECT 2 474
2 FTD versus non-FTD: Multiple-headed camera rCBF SPECT3 135
3 FTD versus AD: Single-headed camera rCBF SPECT 3 309
4 FTD versus AD: Multiple-headed camera rCBF SPECT 8 421
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Flow diagram.
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Caption
'Risk of bias' and applicability concerns summary: review authors' judgements about each domain for each included study
Figure 3
Caption
'Risk of bias' and applicability concerns graph: review authors' judgements about each domain presented as percentages
across included studies
Figure 4 (Analysis 1) 
Caption
Forest plot of single-headed and multiple-headed camera rCBF SPECT for differentiating frontotemporal dementia (FTD)
from non-FTD. The studies are ordered according to study design, reference standard (RS) and sensitivity. TP: true positive;
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FP: false positive; FN: false negative; TN: true negative; CI: confidence interval.
Figure 5 (Analysis 1) 
Caption
Summary ROC plot of single-headed and multiple-headed camera rCBF SPECT for differentiating frontotemporal dementia
(FTD) from non-FTD. Each symbol represents the sensitivity and specificity of a study. Different colours are used to indicate
the two camera types and different symbols are used to indicate study design.
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Forest plot of single-headed and multiple-headed camera rCBF SPECT for differentiating frontotemporal dementia (FTD)
from Alzheimer's disease dementia (AD). The studies are ordered according to study design, reference standard (RS) and
sensitivity. TP: true positive; FP: false positive; FN: false negative; TN: true negative; CI: confidence interval.
Figure 7 (Analysis 2) 
Caption
Summary ROC plot of single-headed and multiple-headed camera rCBF SPECT for differentiating frontotemporal dementia
(FTD) from Alzheimer's disease dementia (AD). Each symbol represents the sensitivity and specificity of a study. Different
colours are used to indicate the two camera types and different symbols are used to indicate study design.
Sources of support 
Internal sources
No sources of support provided
External sources
NIHR, UK
This review was supported by the National Institute for Health Research, via a Cochrane Programme Grant to the
Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the
authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of
Health
Feedback 
Appendices 
1 Classification of dementia
WHO ICD-10
DTA 24 Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal...
58 / 69
Dementia
G1. Evidence of each of the following:
(1) A decline in memory, which is most evident in the learning of new information, although in more severe cases the
recall of previously learned information may be also affected. The impairment applies to both verbal and non-verbal
material. The decline should be objectively verified by obtaining a reliable history from an informant, supplemented, if
possible, by neuropsychological tests or quantified cognitive assessments. The severity of the decline, with mild
impairment as the threshold for diagnosis, should be assessed as follows:
Mild: a degree of memory loss sufficient to interfere with everyday activities, though not so severe as to be
incompatible with independent living. The main function affected is the learning of new material. For example, the
individual has difficulty in registering, storing and recalling elements in daily living, such as where belongings have
been put, social arrangements, or information recently imparted by family members.
Moderate: a degree of memory loss which represents a serious handicap to independent living. Only highly learned
or very familiar material is retained. New information is retained only occasionally and very briefly. The individual is
unable to recall basic information about where he lives, what he has recently been doing, or the names of familiar
persons.
Severe: a degree of memory loss characterised by the complete inability to retain new information. Only fragments
of previously learned information remain. The subject fails to recognise even close relatives.
(2) A decline in other cognitive abilities characterised by deterioration in judgement and thinking, such as planning and
organising, and in the general processing of information. Evidence for this should be obtained when possible from
interviewing an informant, supplemented, if possible, by neuropsychological tests or quantified objective assessments.
Deterioration from a previously higher level of performance should be established. The severity of the decline, with mild
impairment as the threshold for diagnosis, should be assessed as follows:
Mild: the decline in cognitive abilities causes impaired performance in daily living, but not to a degree making the
individual dependent on others. More complicated daily tasks or recreational activities cannot be undertaken.
Moderate: the decline in cognitive abilities makes the individual unable to function without the assistance of another
in daily living, including shopping and handling money. Within the home, only simple chores are preserved. Activities
are increasingly restricted and poorly sustained.
Severe: the decline is characterised by an absence, or virtual absence, of intelligible ideation. The overall severity of
the dementia is best expressed as the level of decline in memory or other cognitive abilities, whichever is the more
severe (e.g. mild decline in memory and moderate decline in cognitive abilities indicate a dementia of moderate
severity).
G2. Preserved awareness of the environment during a period of time long enough to enable the unequivocal
demonstration of G1. When there are superimposed episodes of delirium the diagnosis of dementia should be deferred.
G3. A decline in emotional control or motivation, or a change in social behaviour, manifest as at least one of the following:
emotional lability;
irritability;
apathy;
coarsening of social behaviour.
G4. For a confident clinical diagnosis, G1 should have been present for at least six months; if the period since the
manifest onset is shorter, the diagnosis can only be tentative.
Comments: The diagnosis is further supported by evidence of damage to other higher cortical functions, such as aphasia,
agnosia, apraxia.
Judgements about independent living or the development of dependence (upon others) need to take account of the cultural
expectation and context.
Dementia is specified here as having a minimum duration of six months to avoid confusion with reversible states with
identical behavioural syndromes, such as traumatic subdural haemorrhage (S06.5), normal pressure hydrocephalus (G91.2)
and diffuse or focal brain injury (S06.2 and S06.3).
Neary criteria for behavioural variant of frontotemporal dementia
I. Core diagnostic features
A. Insidious onset and gradual progression
B. Early decline in social interpersonal conduct
C. Early impairment in regulation of personal conduct
D. Early emotional blunting
E. Early loss of insight
II. Supportive diagnostic features
A. Behavioural disorder
1. Decline in personal hygiene and grooming
2. Mental rigidity and inflexibility
3. Distractibility and impersistence
4. Hyperorality and dietary changes
5. Perseverative and stereotyped behaviour
6. Utilisation behaviour
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B. Speech and language
1. Altered speech output
a. Aspontaneity and economy of speech
b. Press of speech
2. Stereotypy of speech
3. Echolalia
4. Perseveration
5. Mutism
C. Physical signs
1. Primitive reflexes
2. Incontinence
3. Akinesia, rigidity, and tremor
4. Low and labile blood pressure
D. Investigations
1. Neuropsychology: significant impairment on frontal lobe tests in the absence of severe amnesia, aphasia, or
perceptuospatial disorder
2. Electroencephalography (EEG): normal on conventional EEG despite clinically evident dementia
3. Brain imaging (structural and/or functional): predominant frontal and/or anterior temporal abnormality
2 Search strategies
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Source
Search strategy Hits
retrieved
1. MEDLINE In-
process and other
non-indexed citations
and MEDLINE 1950-
present (Ovid SP)
 
1. Tomography, Emission-Computed, Single-Photon/ or Tomography, Emission-Computed/
2. SPECT.ti,ab.
3. SPET.ti,ab.
4. single photon emission tomography.ti,ab.
5. single photon emission computed tomography.ti,ab.
6. "SPECT/CT".ti,ab.
7. or/1-6
8. exp Dementia/
9. Delirium/
10. Delirium, Dementia, Amnestic, Cognitive Disorders/
11. dement*.ti,ab.
12. alzheimer*.ti,ab.
13. (lewy* adj2 bod*).ti,ab.
14. (chronic adj2 cerebrovascular).ti,ab.
15. ("organic brain disease" or "organic brain syndrome").ti,ab.
16. "benign senescent forgetfulness".ti,ab.
17. (cerebr* adj2 deteriorat*).ti,ab.
18. (cerebral* adj2 insufficient*).ti,ab.
19. (pick* adj2 disease).ti,ab.
20. "Frontotemporal lobar degeneration".ti,ab.
21. "progressive non-fluent aphasia".ti,ab.
22. "primary progressive aphasia".ti,ab.
23. (FTD or FTLD).ti,ab.
24. Frontotemporal Lobar Degeneration/
25. Primary Progressive Nonfluent Aphasia/
26. Aphasia, Primary Progressive/
27. or/8-26
28. 7 and 27
29. (animals not (humans and animals)).sh.
30. 28 not 29
31. (2012* or 2013*).ed.
32. 30 and 31
July
2012:
2387
June
2013:
161
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Source
Search strategy Hits
retrieved
2. EMBASE
1980-2013 June 21
(Ovid SP)
 
1. single photon emission computer tomography/
2. SPECT.ti,ab.
3. SPET.ti,ab.
4. single photon emission tomography.ti,ab.
5. single photon emission computed tomography.ti,ab.
6. ("99mTc-SPECT" or "99mTc SPECT" or "99mTc SPECT/CT").ti,ab.
7. or/1-6
8. dementia/
9. delirium/
10. dement*.ti,ab.
11. alzheimer*.ti,ab.
12. (lewy* adj2 bod*).ti,ab.
13. (chronic adj2 cerebrovascular).ti,ab.
14. ("organic brain disease" or "organic brain syndrome").ti,ab.
15. "benign senescent forgetfulness".ti,ab.
16. (cerebr* adj2 deteriorat*).ti,ab.
17. (cerebral* adj2 insufficient*).ti,ab.
18. (pick* adj2 disease).ti,ab.
19. "Frontotemporal lobar degeneration".ti,ab.
20. "progressive non-fluent aphasia".ti,ab.
21. "primary progressive aphasia".ti,ab.
22. (FTD or FTLD).ti,ab.
23. frontotemporal dementia/
24. progressive nonfluent aphasia/
25. primary progressive aphasia/
26. or/8-25
27. 7 and 26
28. (2012* OR 2013*).em.
29. 27 and 28
July
2012:
3439
June
2013:
426
DTA 24 Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal...
62 / 69
 
Source
Search strategy Hits
retrieved
3. PSYCINFO
1806-July week 1
2012 (Ovid SP)
 
1. SPECT.mp.
2. SPET.mp.
3. single photon emission tomography.ti,ab.
4. single photon emission computed tomography.ti,ab.
5. ("99mTc-SPECT" or "99mTc SPECT" or "99mTc SPECT/CT").ti,ab.
6. or/1-5
7. exp Dementia/
8. Delirium/
9. dement*.ti,ab.
10. alzheimer*.ti,ab.
11. (lewy* adj2 bod*).ti,ab.
12. (chronic adj2 cerebrovascular).ti,ab.
13. ("organic brain disease" or "organic brain syndrome").ti,ab.
14. "benign senescent forgetfulness".ti,ab.
15. (cerebr* adj2 deteriorat*).ti,ab.
16. (cerebral* adj2 insufficient*).ti,ab.
17. (pick* adj2 disease).ti,ab.
18. "Frontotemporal lobar degeneration".ti,ab.
19. "progressive non-fluent aphasia".ti,ab.
20. "primary progressive aphasia".ti,ab.
21. (FTD or FTLD).ti,ab.
22. or/7-21
23. 6 and 22
24. 2012*.up. or 2013*.up.
25. 23 and 24
July
2012:
657
June
2013: 76
4. Biosis previews
1926 to present (ISI
Web of Knowledge)
 
Topic=(SPECT OR SPET OR "single photon emission tomography" OR "single photon
emission computed tomography" OR "99mTc-SPECT" OR "99mTc SPECT" OR "99mTc
SPECT/CT") AND Topic=(dement* OR alzheimer* OR FTLD OR FTD OR "primary
progressive aphasia" OR "progressive non-fluent aphasia" OR "frontotemporal lobar
degeneration" OR "frontolobar degeneration" OR "frontal lobar degeneration" OR "pick*
disease" OR "lewy bod*")
Timespan=All Years. Databases=BIOSIS Previews.
Lemmatization=On
July
2012:
1691
June
2013: 77
5. Web of Science
and conference
proceedings (1945-
present)
 
Topic=(SPECT OR SPET OR "single photon emission tomography" OR "single photon
emission computed tomography" OR "99mTc-SPECT" OR "99mTc SPECT" OR "99mTc
SPECT/CT") AND Topic=(dement* OR alzheimer* OR FTLD OR FTD OR "primary
progressive aphasia" OR "progressive non-fluent aphasia" OR "frontotemporal lobar
degeneration" OR "frontolobar degeneration" OR "frontal lobar degeneration" OR "pick*
disease" OR "lewy bod*")
Timespan=records processed from 2011-07-01 - 2013-06-23. Databases=SCI-EXPANDED,
SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH.
Lemmatization=On
July
2012:
2556
June
2013:
276
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Source
Search strategy Hits
retrieved
6. LILACS (BIREME) demências OR dementia OR dementias OR demência OR Alzheimer OR Alzheimers OR
Alzheimer’s OR cognitive OR cognitive OR cognitive OR cognition OR "déficit cognitive" OR
cognición OR cognição OR Memória OR memory OR Memoria OR "frontotemporal lobar
degeneration" OR "degeneração lobar frontotemporal" OR FTLD OR FTD OR "pick’s
disease" OR "primary progressive aphasia" [Words] and 99mTc-HmPAO OR SPECT OR
"Single photon emission computerized tomography" OR SPET OR "Single photon emission
tomography" OR "tomografía computarizada de emisión de fotón único" [Words] and 2012
OR 2013 [Country, year publication]
July
2012: 98
June
2013: 2
TOTAL before de-duplication July
2012:
10828
June
2013:
1018
TOTAL after de-dupe and first-assess July
2012:
302
June
2013: 86
3 Information for extraction to proforma
Bibliographic details of primary paper:
Author, title of study, year and journal
 Details of index test:
Method of [index test] administration, including who administered and interpreted the test, and their training
Thresholds used to define positive and negative tests
 Reference standard:
Reference standard used
Method of [reference standard] administration, including who administered the test and their training
 Study population:
Number of subjects
Age
Gender
Other characteristics, e.g. Apolipoprotein E (APOE) genotype
Settings: i) community; ii) primary care; iii) secondary care outpatients; iv) secondary care inpatients and residential care
Participant recruitment
Sampling procedures
Time between index test and reference standard
Proportion of people with dementia in sample
Subtype and stage of dementia if available
MCI (mild cognitive impairment) definition used (if applicable)
Duration of follow-up in delayed verification studies
Attrition and missing data
 
4 Assessment of methodological quality QUADAS-2 tool
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DOMAIN PATIENT SELECTION INDEX TEST  REFERENCE
STANDARD
FLOW AND TIMING 
Description Describe methods of
patient selection;
 describe included
patients (prior testing,
presentation, intended
use of index test and
setting)
Describe the index
test and how it was
conducted and
interpreted
Describe the reference
standard and how it
was conducted and
interpreted
Describe any patients who did not
receive the index test(s) and/or
reference standard or who were
excluded from the 2 x 2 table
(refer to flow diagram); describe
the time interval and any
interventions between index test(s)
and reference standard
Signalling
questions
(yes/no/unclear)
Was a consecutive or
random sample of
patients enrolled?
Were the index test
results interpreted
without knowledge of
the results of the
reference standard?
Is the reference
standard likely to
correctly classify the
target condition?
Was there an appropriate interval
between index test(s) and
reference standard?
Was a case-control
design avoided?
If a threshold was
used, was it
prespecified?
Were the reference
standard results
interpreted without
knowledge of the
results of the index
test?
Did all patients receive a reference
standard?
Did the study avoid
inappropriate
exclusions?
Did all patients receive the same
reference standard?
Were all patients included in the
analysis?
Risk of bias:
high/low/unclear
Could the selection of
patients have
introduced bias?
Could the conduct or
interpretation of the
index test have
introduced bias?
Could the reference
standard, its conduct,
or its interpretation
have introduced bias?
Could the patient flow have
introduced bias? 
Concerns
regarding
applicability:
high/low/unclear
Are there concerns that
the included patients do
not match the review
question?
Are there concerns
that the index test, its
conduct, or
interpretation differ
from the review
question?
Are there concerns that
the target condition as
defined by the
reference standard
does not match the
review question?
 -
     
5 Anchoring statements for methodological quality assessment using the QUADAS-2 tool
Question Judgement Explanation
Patient selection
 
Was the sampling method
appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where sampling was used, the designs least likely to cause bias are consecutive
sampling or random sampling. Sampling based on volunteers or selecting
subjects from a clinic or research resource is prone to bias.
Was a case-control or similar
design avoided?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Designs similar to a case-control design the may introduce bias are those
designs where the study team deliberately increase or decrease the proportion of
subjects with the target condition, which may not be representative. Some case-
control methods may already be excluded if they mix subjects from various
settings.
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Question Judgement Explanation
Are exclusion criteria
described and appropriate?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Study will be automatically graded as unclear if exclusions are not detailed
(pending contact with study authors). Where exclusions are detailed, the study
will be graded as 'low risk' if exclusions are felt to be appropriate by the review
authors. Certain exclusions common to many studies of dementia are: medical
instability; terminal disease; alcohol/substance misuse; concomitant psychiatric
diagnosis; other neurodegenerative condition. Exclusions are not felt to be
appropriate if 'difficult to diagnose' patients are excluded. Post hoc and
inappropriate exclusions will be labelled 'high risk' of bias.
Index test
Was rCBF SPECT
assessment/interpretation
performed without knowledge
of reference standard?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
 
Terms such as "blinded" or "independently and without knowledge of" are
sufficient and full details of the blinding procedure are not required. Interpretation
of the results of the index test may be influenced by knowledge of the results of
reference standard. If the index test is always interpreted prior to the reference
standard then the person interpreting the index test cannot be aware of the
results of the reference standard and so this item could be rated as 'yes'.
Were rCBF SPECT
thresholds prespecified?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
For scales and biomarkers there is often a reference point (in units or categories)
above which subjects are classified as 'test positive'; this may be referred to as a
threshold, clinical cut-off or dichotomisation point. A study is classified as at high
risk of bias if the authors define the optimal cut-off post-hoc based on their own
study data because selecting the threshold to maximise sensitivity, specificity or
both may lead to overoptimistic measures of test performance.
Certain papers may use an alternative methodology for analysis that does not
use thresholds and these papers should be classified as not applicable.
Reference standard
 
Is the assessment used for
clinical diagnosis of FTD
acceptable?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
 
Ante-mortem clinical diagnosis of FTD will be based on recognised diagnostic
criteria, Lund and Manchester Groups 1994 or Neary 1998 or McKhann 2001
criteria (as previously outlined) or histopathological diagnosis and/or genetic
mutation known to be causative of FTD (if available).
For other types of dementia potentially used to define control groups in
our review, clinical diagnoses of dementia will include all-cause
(unspecified) dementia, using any recognised diagnostic criteria, for
example DSM-IV and ICD-10 (American Psychiatric Association 2013; WHO
2010). NINCDS-ADRDA (National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and
Related Disorders Association) criteria are the most accepted ante-
mortem clinical consensus gold standard for Alzheimer's dementia (McKhann
1984), defining three ante-mortem groups: 'probable', 'possible' and
'unlikely' Alzheimer's dementia. The Consortium to Establish a Registry for
Alzheimer's Disease (CERAD) (Mirra 1991), ICD10 and DSM-IV
definitions of AD are also acceptable. National Institute of Neurological
Disorders and Stroke-Association Internationale pour la Recherche et
l'Enseignement en Neurosciences (NINDS-AIREN) (Román 1993),
Alzheimer’s Disease Diagnostic and Treatment Centers (ADDTC) (Chui 1992
), DSM-IV, ICD-10, and the Cambridge Mental Disorders of the Elderly
Examination (CAMDEX) criteria (Hendrie 1988) are all acceptable for the
diagnosis of vascular dementia (VD).
Where the criteria used for assessment are not familiar to the review authors or
to the Cochrane Dementia and Cognitive Improvement Group ('unclear') this item
should be classified as at high risk of bias.
 
Was clinical assessment for
FTD performed without
knowledge of the rCBF
SPECT biomarker?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Terms such as "blinded" or "independently and without knowledge of" are
sufficient and full details of the blinding procedure are not required. Interpretation
of the results of the reference standard may be influenced by knowledge of the
results of index test.
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Question Judgement Explanation
Patient flow
Was there an appropriate
interval between rCBF
SPECT and clinical
assessment?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
 
For cross-sectional case-control studies the index test and application of the
reference standard are ideally administered on the same day, but a delay is
unlikely to introduce bias as the condition of dementia is irreversible.
For longitudinal studies, the time between reference standard and index
test will influence the accuracy (Geslani 2005; Okello 2009; Visser 2006), and
therefore we will note time as a separate variable (both within and between
studies) and will test its influence on the diagnostic accuracy. We have set a
minimum mean time to follow-up assessment of one year for longitudinal cohort
(delayed verification) studies.
Did all subjects get the same
assessment for dementia
regardless of rCBF SPECT
result?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
There may be scenarios where subjects who score 'test positive' on the index
test have a more detailed assessment. Where dementia assessment (i.e.
reference standard) differs between groups of subjects this should be classified
as at high risk of bias.
 
Were all patients who
received rCBF SPECT
assessment included in the
final analysis?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
If the number of patients enrolled differs from the number of patients included in
the 2 x 2 table then there is the potential for bias.
If participant data missing due to drop-out differ systematically from those for the
remaining participants, then estimates of test performance may differ. If drop-
outs occur these should be accounted for; a maximum proportion of drop-outs
has been specified as 20% in order to be scored as low risk of bias, but this will
depend upon length of follow up in longitudinal cohort studies.
 
Were missing or
uninterpretable rCBF SPECT
results reported?
No = high
risk of bias
Yes = low
risk of bias
Unclear =
unclear risk
of bias
Where missing or uninterpretable results are reported, and if there is substantial
attrition (we have set an arbitrary value of 50% missing data), this should be
scored as at high risk of bias. If these results are not reported, this should be
scored as 'unclear' and authors will be contacted.
Anchoring statements to assist with assessment of applicability
Question Explanation 
 
Were included patients
representative of the general
population of interest?
The included patients should match the intended population as described in the review
question. The review authors should consider population in terms of symptoms; pre-testing;
potential disease prevalence; setting.
If there are clear grounds for suspecting an unrepresentative spectrum the item should be
rated 'poor applicability'.
Index test
Were sufficient data on rCBF
SPECT application given for
the test to be repeated in an
independent study?
 
Variation in technology, test execution, and test interpretation may affect estimate of
accuracy. In addition, the background and training/expertise of the assessor should be
reported and taken into consideration. If the rCBF SPECT biomarker was not performed
consistently this item should be rated 'poor applicability'.
Reference standard
 
Was clinical diagnosis of
dementia made in a manner
similar to current clinical
practice?
 
For many reviews, clinical diagnosis of dementia will be made using standard clinical criteria.
For certain reviews an applicability statement relating to reference standard may not be
applicable. There is the possibility that a current reference standard, although valid, may
diagnose a far smaller proportion of subjects with disease than in usual clinical practice. In
this instance the item should be rated 'poor applicability'.
rCBF= regional cerebral blood flow; SPECT= single-photon emission computerised tomography; FTD=frontotemporal
dementia; DSM-IV= DSM=Diagnostic and Statistical Manual of Mental Disorders-IV; ICD-10=International Classificatio of
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Diseases-10
Review question and inclusion criteria
Category Review question Inclusion criteria
Participants Participants with suspected FTD
(Primary Objective 1)
 
 
Participants fulfilling the criteria for the clinical diagnosis of any forms of
dementia in secondary and tertiary care setting
Index test rCBF SPECT biomarker rCBF SPECT biomarker
Target
condition
Frontotemporal dementia (FTD)
 
Initial diagnosis of FTD
 
Differential diagnosis of FTD from other dementia subtypes
 
Reference
standard
Diagnosis of FTD as determined by
the Manchester-Lund or NINDS
criteria,
histopathological confirmation of
diagnosis and/or genetic mutation
known to be causative of FTD (if
available)
 
Diagnosis of FTD as determined by the Manchester-Lund or NINDS
criteria,
histopathological confirmation of diagnosis and/or genetic mutation known
to be causative of FTD (if available)
 
NINCDS-ADRDA criteria are the most accepted ante-mortem clinical
consensus gold standard for Alzheimer's dementia, defining three ante-
mortem groups: 'probable', 'possible' and 'unlikely' Alzheimer's dementia.
CERAD, ADDTC, ICD-10 and DSM-IV definitions of ADD were also
acceptable.
 
NINDS-AIREN, ADDTC, DSM-IV, ICD-10, CAMDEX criteria were
acceptable for VaD
 
Outcome N/A Data to construct 2 x 2 table
Study design N/A Longitudinal cohort studies and nested case-control studies if
they incorporate a delayed-verification design (case-control
nested in cohort studies) (Objectives)
Cross-sectional studies in which: i) rCBF SPECT results and the clinical
diagnostic criteria were obtained within a narrow time-frame, and ii) FTD
patients were differentiated from patients with other dementia subtypes
 
In assessing individual items, the assessment of 'unclear' should be given only if there is genuine uncertainty.  In these
situations review authors will contact the relevant study teams for additional information.
FTD = frontotemporal dementia; rCBF=; SPECT=; NINDS = National Institute of Neurological Disorders and Stroke;
NINCDS-ADRDA=National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease;
CERAD=; ADDTC=ICD-10; DSM-IV=; ADD=Alzheimer's disease dementia; NINDS-AIREN=; CAMDEX=; VaD=vascular
dementia;
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